US20070156232A1 - Medical Device with Coating that Promotes Endothelial Cell Adherence - Google Patents
Medical Device with Coating that Promotes Endothelial Cell Adherence Download PDFInfo
- Publication number
- US20070156232A1 US20070156232A1 US11/562,931 US56293106A US2007156232A1 US 20070156232 A1 US20070156232 A1 US 20070156232A1 US 56293106 A US56293106 A US 56293106A US 2007156232 A1 US2007156232 A1 US 2007156232A1
- Authority
- US
- United States
- Prior art keywords
- matrix
- medical device
- cells
- antibodies
- endothelial cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
- A61F2/06—Blood vessels
- A61F2/07—Stent-grafts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/08—Carbon ; Graphite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/30—Inorganic materials
- A61L27/303—Carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/08—Materials for coatings
- A61L29/10—Inorganic materials
- A61L29/103—Carbon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L29/126—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/02—Inorganic materials
- A61L31/022—Metals or alloys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/082—Inorganic materials
- A61L31/084—Carbon; Graphite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/069—Vascular Endothelial cells
- C12N5/0692—Stem cells; Progenitor cells; Precursor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
- A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/422—Anti-atherosclerotic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Definitions
- the present invention relates to the field of medical devices implanted in vessels within the body. More particularly, the present invention relates to stents or synthetic grafts implanted in blood vessels that incorporate a matrix which promotes adherence of endothelial cells to the stent or synthetic graft.
- Atherosclerosis is one of the leading causes of death and disability in the world. Atherosclerosis involves the deposition of fatty plaques on the lumenal surface of arteries. The deposition of fatty plaques on the lumenal surface of the artery causes narrowing of the cross-sectional area of the artery. Ultimately, this deposition blocks blood flow distal to the lesion causing ischemic damage to the tissues supplied by the artery.
- Coronary arteries supply the heart with blood.
- Coronary artery atherosclerosis disease (CAD) is the most common, serious, chronic, life-threatening illness in the United States, affecting more than 11 million persons.
- the social and economic costs of coronary atherosclerosis vastly exceed that of most other diseases.
- Narrowing of the coronary artery lumen causes destruction of heart muscle resulting first in angina, followed by myocardial infarction and finally death.
- myocardial infarctions There are over 1.5 million myocardial infarctions in the United States each year. Six hundred thousand (or 40%) of those patients suffer an acute myocardial infarction and more than three hundred thousand of those patients die before reaching the hospital. ( Harrison's Principles of Internal Medicine, 14 th Edition, 1998).
- CAD can be treated using percutaneous translumenal coronary balloon angioplasty (PTCA). More than 400,000 PTCA procedures are performed each year in the United States.
- PTCA percutaneous translumenal coronary balloon angioplasty
- a balloon catheter is inserted into a peripheral artery and threaded through the arterial system into the blocked coronary artery.
- the balloon is then inflated, the artery stretched, and the obstructing fatty plaque flattened, thereby increasing the cross-sectional flow of blood through the affected artery.
- the therapy does not usually result in a permanent opening of the affected coronary artery. As many as 50% of the patients who are treated by PTCA require a repeat procedure within six months to correct a re-narrowing of the coronary artery.
- restenosis this re-narrowing of the artery after treatment by PTCA is called restenosis.
- recoil and shrinkage of the vessel are followed by proliferation of medial smooth muscle cells in response to injury of the artery from PTCA.
- proliferation of smooth muscle cells is mediated by release of various inflammatory factors from the injured area including thromboxane A 2, platelet derived growth factor (PDGF) and fibroblast growth factor FGF).
- PDGF platelet derived growth factor
- FGF fibroblast growth factor
- Stents are metal scaffolds that are positioned in the diseased vessel segment to create a normal vessel lumen. Placement of the stent in the affected arterial segment prevents recoil and subsequent closing of the artery. Stents can also prevent local dissection of the artery along the medial layer of the artery. By maintaining a larger lumen than that created using PTCA alone, stents reduce restenosis by as much as 30%. Despite their success, stents have not eliminated restenosis entirely. (Suryapranata et al. 1998. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 97:2502-2502).
- Narrowing of the arteries can occur in vessels other than the coronary arteries, including the aortoiliac, infrainguinal, distal profinda femoris, distal popliteal, tibial, subclavian and mesenteric arteries.
- PID peripheral artery atherosclerosis disease
- the prevalence of peripheral artery atherosclerosis disease (PAD) depends on the particular anatomic site affected as well as the criteria used for diagnosis of the occlusion.
- physicians have used the test of intermittent claudication to determine whether PAD is present. However, this measure may vastly underestimate the actual incidence of the disease in the population. Rates of PAD appear to vary with age, with an increasing incidence of PAD in older individuals.
- PAD can be treated using percutaneous translumenal balloon angioplasty (PTA).
- PTA percutaneous translumenal balloon angioplasty
- the use of stents in conjunction with PTA decreases the incidence of restenosis.
- the post-operative results obtained with medical devices such as stents do not match the results obtained using standard operative revascularization procedures, i.e., those using a venous or prosthetic bypass material.
- PAD is treated using bypass procedures where the blocked section of the artery is bypassed using a graft.
- the graft can consist of an autologous venous segment such as the saphenous vein or a synthetic graft such as one made of polyester, polytetrafluoroethylene (PTFE), or expanded polytetrafluoroethylene (ePTFE).
- PTFE polytetrafluoroethylene
- ePTFE expanded polytetrafluoroethylene
- stents With stents, the approach has been to coat the stents with various anti-thrombotic or anti-restenotic agents in order to reduce thrombosis and restenosis.
- impregnating stents with radioactive material appears to inhibit restenosis by inhibiting migration and proliferation of myofibroblasts.
- Irradiation of the treated vessel can pose safety problems for the physician and the patient. In addition, irradiation does not permit uniform treatment of the affected vessel.
- stents have also been coated with chemical agents such as heparin or phosphorylcholine, both of which appear to decrease thrombosis and restenosis.
- chemical agents such as heparin or phosphorylcholine, both of which appear to decrease thrombosis and restenosis.
- heparin and phosphbrylcholine appear to markedly reduce restenosis in animal models in the short term, treatment with these agents appears to have no long-term effect on preventing restenosis.
- heparin can induce thrombocytopenia, leading to severe thromboembolic complications such as stroke. Nonetheless, it is not feasible to load stents with sufficient therapeutically effective quantities of either heparin or phosphorylcholine to make treatment of restenosis in this manner practical.
- Synthetic grafts have been treated in a variety of ways to reduce postoperative restenosis and thrombosis. (Bos et al. 1998. Small-Diameter Vascular Graft Prostheses:Current Status Achives Physio. Biochem . 106:100-115). For example, composites of polyurethane such as meshed polycabonate urethane have been reported to reduce restenosis as compared with ePTFE grafts. The surface of the graft has also been modified using radiofrequency glow discharge to add polyterephalate to the ePTFE graft. Synthetic grafts have also been impregnated with biomolecules such as collagen. However, none of these approaches has significantly reduced the incidence of thrombosis or restenosis over an extended period of time.
- endothelial cells possess certain intrinsic characteristics such as cell regulatory molecules that decrease the incidence of thrombosis or restenosis, stimulating the development of an endothelial cell monolayer on the surface of stents or synthetic grafts may prevent both restenosis and thrombosis.
- endothelial cells possess certain intrinsic characteristics such as cell regulatory molecules that decrease the incidence of thrombosis or restenosis
- stimulating the development of an endothelial cell monolayer on the surface of stents or synthetic grafts may prevent both restenosis and thrombosis.
- VEGF vascular endothelial growth factor
- Synthetic grafts have also been seeded with endothelial cells, but the clinical results with endothelial seeding have been generally poor, i.e., low post-operative patency rates (Lio et al. 1998. New concepts and Materials in Microvascular Grafting: Prosthetic Graft Endothelial Cell Seeding and Gene Therapy. Microsurgery 18:263-256).
- the invention provides methods and compositions for coating medical devices with a matrix that promotes adherence of endothelial cells to a medical device.
- the matrix incorporates antibodies that stimulate adherence of endothelial cells to the surface of the medical device.
- medical device refers to a device that is introduced temporarily or permanently into a mammal for the prophylaxis or therapy of a medical condition. These devices include any that are introduced subcutaneously, percutaneously or surgically to rest within an organ, tissue or lumen.
- Medical devices may include stents, covered stents such as those covered with polytetrafluoroethylene (PTFE), or expanded polytetrafluoroethylene (ePTFE), synthetic grafts, artificial heart valves, artificial hearts and fixtures to connect the prosthetic organ to the vascular circulation, venous valves, abdominal aortic aneurysm (AAA) grafts, inferior venal caval filters, permanent drug infision catheters, embolic coils, embolic materials used in vascular embolization (e.g., PVA foams), and vascular sutures.
- PTFE polytetrafluoroethylene
- ePTFE expanded polytetrafluoroethylene
- Coating of the medical device with the compositions and methods of this invention may stimulate the development of an endothelial cell layer on the surface of the medical device, thereby preventing restenosis as well as other thromboembolic complications that result from implantation of the medical device.
- Synthetic grafts and stents can be used for treating CAD or PAD.
- a stent or synthetic graft may be coated with a matrix incorporating antibodies that stimulate adherence of circulating progenitor endothelial cells to the medical device.
- the antibodies may comprise monoclonal antibodies reactive with endothelial cell surface antigens such as CD34, an antigen expressed on the surface of progenitor endothelial cells.
- Fab fragments of the monoclonal antibody may be used.
- monoclonal antibodies directed against other endothelial surface antigens such as KDP, or Tie-2, may also be used.
- a single type of antibody that reacts with one antigen may be used.
- a plurality of different antibodies directed against different endothelial cell surface antigens may be mixed together and added to the matrix.
- the matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol.
- the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin or amorphous carbon.
- the matrix may comprise several layers with a first layer being composed of synthetic or naturally occurring materials and a second layer composed of antibodies. The layers may be ordered sequentially, with the first layer directly in contact with the stent or synthetic graft surface and the second layer having one surface in contact with the first layer and the opposite surface in contact with the vessel lumen.
- the matrix may comprise fullerenes, where the fullerenes range from about C60 to about C100.
- the fullerenes may also be arranged as nanotubes, that incorporate molecules or proteins.
- the fullerenes matrix may also be mixed with PTFE or ePTFE, or antibodies. Alternatively, the PTFE or ePTFE may be layered first on the medical device followed by a second layer of fullerenes.
- the matrix may be noncovalently or covalently attached to the medical device.
- Antibodies may be covalently attached to the matrix using hetero- or homobifunctional cross-linking reagents.
- the artery may be the either a coronary artery or a peripheral artery such as the femoral artery.
- FIG. 1 shows an antibody tethered covalently to the matrix by a cross-linking molecule.
- FIG. 2 shows a diagram of the C60O molecule anchoring the matrix.
- the present invention provides methods and compositions that involve coating a medical device such as a stent or synthetic graft with a matrix which is then used to coat the medical device.
- the matrix incorporates a therapeutically effective amount of at least one type of antibody that promotes adherence of endothelial cells to the medical device. Following adherence, the endothelial cells differentiate and proliferate on the surface of the matrix. The presence of endothelial cells on the medical device reduces the occurrence of restenosis and thrombosis after medical device implantation into a vessel.
- antibody refers to one type of monoclonal or polyclonal antibody, where the monoclonal or polydonal antibody binds to one antigen or a functional equivalent of that antigen.
- the term antibody encompasses any fragment of an antibody such as Fab, F(ab′) 2 or Fc fragments. (An antibody encompasses a plurality of individual antibody molecules equal to 6.022 ⁇ 10 23 molecules per mole of antibody).
- a “therapeutically effective amount of the antibody” means the amount of an antibody that promotes adherence of endothelial cells to the medical device.
- the amount of an antibody needed to practice the claimed invention varies with the nature of the antibody used. For example, the amount of an antibody used will depend on the binding constant between the antibody and the antigen against which it reacts. It is well known to those of ordinary skill in the art how to determine therapeutically effective amounts of an antibody to use with a particular antigen.
- medical device refers to a device that is introduced temporarily or permanently into a mammal for the prophylaxis or therapy of a medical condition. These devices include any that are introduced subcutaneously, percutaneously or surgically to rest within an organ, tissue or lumen.
- Medical devices may include, stents, covered stents such as those covered with PTFE, or ePTFE, synthetic grafts, artificial heart valves, artificial hearts and fixtures to connect the prosthetic organ to the vascular circulation, venous valves, abdominal aortic aneurysm (AAA) grafts, inferior venal caval filters, permanent drug infusion catheters, embolic coils, embolic materials used in vascular embolization (e.g., PVA foams), and vascular sutures,
- restenosis refers to the accumulation of a layer of smooth muscle cells and matrix protein in the intima of an arterial wall. Vessels may become obstructed because of restenosis. After PTCA or PTA, smooth muscle cells from the media and adventitia, which are not normally present in the intima, proliferate and migrate to the intima and secrete proteins, forming an accumulation of smooth muscle cells and matrix protein within the intima. This accumulation causes a narrowing of the lumen of the artery, reducing blood flow distal to the narrowing. As used herein, “inhibition of restenosis” refers to the inhibition of migration and proliferation of smooth muscle cells accompanied by prevention of protein secretion so as to prevent restenosis and the complications arising therefrom.
- the subjects that can be treated using the methods and compositions of this invention may be a mammal, or more specifically, a human, dog cat, pig, rodent or monkey.
- the methods of the present invention may be practiced in vivo or in vitro.
- endothelial cell refers to endothelial cells at any developmental stage, from progenitor to mature. Fully differentiated endothelial cells may be isolated from an artery or vein such as a human umbilical vein, while progenitor endothelial cells are isolated from peripheral blood or bone marrow. The endothelial cells are bound to the medical devices by incubation of the endothelial cells with a medical device coated with the matrix that incorporates an antibody or other agent that adheres to endothelial cells.
- the methods of this invention may be practiced on any artery or vein. Included within the scope of this invention is atherosclerosis of any artery including coronary, infrainguinal, aortoiliac, subclavian, mesenteric and renal arteries. Other types of vessel obstructions, such as those resulting from a dissecting aneurysm are also encompassed by the invention.
- the medical device may be coated with endothelial cells after insertion into a vessel.
- the medical device is coated with the endothelial cells before insertion of the medical device.
- the presence of endothelial cells on the lumenal surface of the medical device inhibits or prevents restenosis and thrombosis.
- Human umbilical vein endothelial cells are obtained from umbilical cords according to the methods of Jaffe, et al., J. Clin. Invest ., 52:2745-2757, 1973, incorporated herein by reference. Briefly, cells are stripped from the blood vessel walls by treatment with collagenase and cultured in gelatin-coated tissue culture flasks in M199 medium containing 10% low endotoxin fetal calf serum, 90 ug/ml preservative-free porcine heparin, 20 ug/ml endothelial cell growth supplement ECGS), glutamine and antibodies.
- Progenitor endothelial cells are isolated from human peripheral blood according to the methods of Asahara et al. (Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997, incorporated herein by reference). Magnetic beads coated with antibody to CD34 are incubated with human peripheral blood. After incubation, bound cells are eluted and can be cultured in M-199 containing 20% fetal bovine serum and bovine brain extract. (Clonetics, San Diego, Calif.). Cells are characterized by fluorescent antibodies to CD45, CD34, CD31, Flk-1, Tie-2, and E-selectin.
- Endothelial cells are transfected with any mammalian expression vectors that contains any cloned genes encoding proteins such as platelet derived growth factor (PDGF), fibroblast growth factor (FGF), or nitric oxide synthase (NOS) using conventional methods.
- PDGF platelet derived growth factor
- FGF fibroblast growth factor
- NOS nitric oxide synthase
- mammalian expression vectors and transfection kits commercially available from Stratagene, San Diego, Calif.
- purified porcine progenitor endothelial cells are transfected with vascular endothelial growth factor (VEGF) using an adenoviral expression vector expressing the VEGF cDNA according to the methods of Rosengart et al.
- VEGF vascular endothelial growth factor
- Monoclonal antibodies useful in the method of the invention may be produced according to the standard techniques of Kobler and Milstein (Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 265:495-497, 1975, incorporated herein by reference). Endothelial cells can be used as the immunogen to produce monoclonal antibodies directed against endothelial cell surface antigens.
- Monoclonal antibodies directed against endothelial cells are prepared by injecting HUVEC or purified progenitor endothelial cells into a mouse or rat. After a sufficient time, the mouse is sacrificed and spleen cells are obtained. The spleen cells are immortalized by fusing them with myeloma cells or with lymphoma cells, generally in the presence of a non-ionic detergent, for example, polyethylene glycol. The resulting cells, which include the fused hybridomas, are allowed to grow in a selective medium, such as HAT-medium, and the surviving cells are grown in such medium using limiting dilution conditions. The cells are grown in a suitable container, e.g., microtiter wells, and the supernatant is screened for monoclonal antibodies having the desired specificity, ie., reactivity with endothelial cell antigens.
- a suitable container e.g., microtiter wells
- useful binding fragments of anti-endothelial cell monoclonal antibodies such as the Fab, F(ab′) 2 , or Fc fragments of these monoclonal antibodies.
- the antibody fragments are obtained by conventional techniques.
- useful binding fragments may be prepared by peptidase digestion of the antibody using papain or pepsin.
- Antibodies of the invention are directed to an antibody of the IgG class from a murine source; however, this is not meant to be a limitation.
- the above antibody and those antibodies having functional equivalency with the above antibody, whether from a murine source, mammalian source including human, or other sources, or combinations thereof are included within the scope of this invention, as well as other classes such as IgM, IgA, IgE, and the like, including isotypes within such classes.
- the term “functional equivalency” means that two different antibodies each bind to the same antigenic site on an antigen, in other words, the antibodies compete for binding to the same antigen.
- the antigen may be on the same or different molecule.
- monoclonal antibodies reacting with the endothelial cell surface antigen CD34 are used.
- Anti-CD34 monoclonal antibodies attached to a solid support have been shown to capture progenitor endothelial cells from human peripheral blood. After capture, these progenitor cells are capable of differentiating into endothelial cells.
- Hybridomas producing monoclonal antibodies directed against CD34 can be obtained from the American Type Tissue Collection. (Rockville, Md).
- monoclonal antibodies reactive with endothelial cell surface antigens Flk-1 or Tie-2 are used.
- Polyclonal antibodies reactive against endothelial cells isolated from the same species as the one receiving the medical device implant may also be used.
- stent herein means any medical device which when inserted into the lumen of a vessel expands the cross-sectional lumen of a vessel.
- the term “stent” includes covered stents such as those covered with PTFE or ePTFE. In one embodiment, this includes stents delivered percutaneously to treat coronary artery occlusions or to seal dissections or aneurysms of the splenic, carotid, iliac and popliteal vessels. In another embodiment, the stent is delivered into a venous vessel.
- the stent can be composed of polymeric or metallic structural elements onto which the matrix is applied or the stent can be a composite of the matrix intermixed with a polymer.
- a deformable metal wire stent can be used, such as that disclosed in U.S. Pat. No. 4,886,062 to Wiktor, incorporated herein by reference.
- a self-expanding stent of resilient polymeric material such as that disclosed in published international patent application WO91/12779 “Intraluminal Drug Eluting Prosthesis”, incorporated herein by reference, can also be used.
- Stents may also be manufactured using stainless steel, polymers, nickel-titanium, tantalum, gold, platinum-irdium, or Elgiloy and MP35N and other ferrous materials.
- Stents are delivered through the body lumen on a catheter to the treatment site where the stent is released from the catheter, allowing the stent to expand into direct contact with the lumenal wall of the vessel. It will be apparent to those skilled in the art that other self-expanding stent designs (such as resilient metal stent designs) could be used with the antibodies and matrices of this invention.
- synthetic graft means any artificial prosthesis having biocompatible characteristics. In one embodiment this includes synthetic grafts made of Dacron (polyethylene terephthalate, PET) or Teflon (ePTFE). In another embodiment, synthetic grafts are composed of polyurethane. In yet a third embodiment, a synthetic graft is composed of an inner layer of meshed polycarbonate urethane and an outer layer of meshed Dacron. It will be apparent to those skilled in the art that any biocompatible synthetic graft can be used with the antibodies and matrices of this invention. (Bos et al. 1998. Small-Diameter Vascular Prostheses: Current Status. Archives Physio Biochem. 106:100-115, incorporated herein by reference). Synthetic grafts can be used for end-to-end anastomosis of vessels or for bypass of a diseased vessel segment.
- the matrix that is used to coat the stent or synthetic graft may be selected from synthetic materials such as polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester or polyethylene glycol.
- the matrix may be selected from naturally occurring substances such as collagen, laminin, heparin, fibrin, cellulose or carbon. A primary requirement for the matrix is that it be sufficiently elastic and flexible to remain unruptured on the exposed surfaces of the stent or synthetic graft.
- Fullerenes The matrix may also comprise a fullerenes (the term “fullerenes” encompasses a plurality of fullerenes molecules). Fullerenes are carbon-cage molecules. The number of carbon (C) molecules in a fullerenes species varies from about C60 to about C100. Fullerenes are produced by high temperature reactions of elemental carbon or of carbon-containing species by processes well known to those skilled in the art; for example, by laser vaporization of carbon, heating carbon in an electric arc or burning of hydrocarbons in sooting flames. (U.S. Pat. No. 5,292,813, to Patel et al., incorporated herein by reference; U.S. Pat. No.
- Fullerenes may be deposited on surfaces in a variety of different ways, including, sublimation, laser vaporization, sputtering, ion beam, spray coating, dip coating, roll-on or brush coating as disclosed in U.S. Pat. No. 5,558,903.
- fullerenes An important feature of fullerenes is their ability to form “activated carbon.”
- the fullerene electronic structure is a system of overlapping pi-orbitals, such that a multitude of bonding electrons are cooperatively presented around the surface of the molecule. ( Chemical and Engineering News . Apr. 8, 1991, page 59, incorporated herein by reference).
- As forms of activated carbon fullerenes exhibit substantial van der Waals forces for weak interactions.
- the adsorptive nature of the fullerenes surface may lend itself to additional modifications for the purpose of directing specific cell membrane interactions.
- lectins or antibodies can be adsorbed to the fullerene surface.
- the fullerene surface may also be chemically modified to present specifically reactive groups to the cell membrane, e.g., oxidants or reductants. Attachment of different molecules to the fullerene surface may be manipulated to create surfaces that selectively bind various cell types, e.g., epithelial cells, fibroblasts, primary explants, or T-cell subpopulations.
- Fullerenes may also form nanotubes that incorporate other atoms or molecules.
- the synthesis and preparation of carbon nanotubes is well known in the art.
- Molecules such as proteins may also be incorporated inside carbon nanotubes.
- nanotubes may be filled with the enzymes, e.g., Zn 2 Cd 2 -metallothionein, cytochromes C and C3, and beta-lactamase after cutting the ends of the nanotube.
- enzymes e.g., Zn 2 Cd 2 -metallothionein, cytochromes C and C3, and beta-lactamase after cutting the ends of the nanotube.
- U.S. Pat. No. 5,338,571 to Mirkin et al. discloses three-dimensional, multilayer fullerene structures that are formed on a substrate surface by (i) chemically modifying fillerenes to provide a bond-forming species; (ii) chemically treating a surface of the substrate to provide a bond-forming species effective to covalently bond with the bond-forming species of the fillerenes in solution; and, (iii) contacting a solution of modified fullerenes with the treated substrate surface to form a fullerene layer covalently bonded to the treated substrate surface.
- the matrix should adhere tightly to the surface of the stent or synthetic graft. Preferably, this is accomplished by applying the matrix in successive thin layers.
- Each layer of matrix may incorporate the antibodies.
- antibodies may be applied only to the layer in direct contact with the vessel lumen.
- Different types of matrices may be applied successively in succeeding layers.
- the antibodies may be covalently or noncovalently coated on the matrix after application of the matrix to the stent.
- the stent In order to coat a medical device such as a stent, the stent is dipped or sprayed with a liquid solution of the matrix of moderate viscosity. After each layer is applied, the stent is dried before application of the next layer.
- a thin, paint-like matrix coating does not exceed an overall thickness of 100 microns.
- a suitable matrix coating solution is prepared by dissolving 480 milligrams (mg) of a drug carrier, such as poly-D, L-lactid (available as R203 of Boehringer Inc., Ingetheim, Germany) in 3 milliliters (ml) of chloroform under aseptic conditions.
- a drug carrier such as poly-D, L-lactid (available as R203 of Boehringer Inc., Ingetheim, Germany) in 3 milliliters (ml) of chloroform under aseptic conditions.
- any biodegradable (or non-biodegradable) matrix that is blood-and tissue-compatible (biocompatible) and can be dissolved, dispersed or emulsified may be used as the matrix if, after application, it undergoes relatively rapid drying to a self-adhesive lacquer- or paint-like coating on the medical device.
- fibrin is clotted by contacting fibrinogen with thrombin.
- the fibrin in the fibrin-containing stent of the present invention has Factor XIII and calcium present during clotting, as described in U.S. Pat. No. 3,523,807 issued to Gerendas, incorporated herein by reference, or as described in published European Patent Application 0366564, incorporated herein by reference, in order to improve the mechanical properties and biostability of the implanted device.
- the fibrinogen and thrombin used to make fibrin in the present invention are from the same animal or human species as that in which the stent will be implanted in order to avoid any inter-species immune reactions, e.g., human anti-cow.
- the fibrin product can be in the form of a fine, fibrin film produced by casting the combined fibrinogen and thrombin in a film and then removing moisture from the film osmotically through a semipermeable membrane.
- a substrate preferably having high porosity or high affinity for either thrombin or fibrinogen
- a fibrinogen solution is contacted with a fibrinogen solution and with a thrombin solution.
- fibrin layer formed by polymerization of fibrinogen on the surface of the medical device.
- Multiple layers of fibrin applied by this method could provide a fibrin layer of any desired thickness.
- the fibrin can first be clotted and then ground into a powder which is mixed with water and stamped into a desired shape in a heated mold (U.S. Pat. No. 3,523,807).
- Increased stability can also be achieved in the shaped fibrin by contacting the fibrin with a fixing agent such as glutaraldehyde or formaldehyde.
- a synthetic graft is coated with collagen
- the methods for preparing collagen and forming it on synthetic graft devices are well known as set forth in U,S. Patent No. 5,851,230 to Weadock et al., incorporated herein by reference.
- This patent describes methods for coating a synthetic graft with collagen.
- Methods for adhering collagen to a porous graft substrate typically include applying a collagen dispersion to the substrate, allowing it to dry and repeating the process.
- Collagen dispersions are typically made by blending insoluble collagen (approximately 1-2% by weight) in a dispersion at acidic pH (a pH in a range of 2 to 4).
- the dispersion is typically injected via syringe into the lumen of a graft and massaged manually to cover the entire inner surface area with the collagen slurry. Excess collagen slurry is removed through one of the open ends of the graft. Coating and drying steps are repeated several times to provide sufficient treatment.
- the stent or synthetic graft is coated with amorphous carbon.
- a method for producing a high-rate, low-temperature deposition of amorphous carbon films in the presence of a fluorinated or other halide gas is described.
- Deposition according to the methods of this invention can be performed at less than 100° C., including ambient room temperature, with a radio-frequency, plasma-assisted, chemical-vapor deposition process.
- the amorphous carbon film produced using the methods of this invention adheres well to many types of substrates, including for example glasses, metals, semiconductors, and plastics.
- amine-containing polymers may be performed as described in U.S. Pat. No. 5,292,813. Chemical modification in this manner allows for direct incorporation of the fullerenes into the stent.
- the fullerenes may be deposited on the surface of the stent or synthetic grafts as described above. (see, WO 99/32184 to Leone et al., incorporated by reference).
- Fullerenes may also be attached through an aldehyde bond (Yamago et al., Chemical Derivatization of Organofullerenes through Oxidation, Reduction and C-O and C-C Bond Forming Reactions. J. Org. Chem., 58 4796-4798 (1998), incorporated herein by reference).
- C60O may also be attached directly through an epoxide group on the fullerene to a stent. The attachment is through a covalent linkage to the oxygen. This compound and the protocols for coupling are commercially available from BuckyUSA. (BuckyUSA, Houston, Tex.).
- Antibodies that promote adherence of progenitor endothelial cells can be incorporated into the matrix, either covalently or noncovalently.
- Antibodies may be incorporated into each layer of matrix by nixing the antibodies with the matrix coating solution.
- the antibodies may be covalently or noncovalently coated on to last layer of matrix that is applied to the medical device.
- the antibodies are added to a solution containing the matrix.
- Fab fragments on anti-CD34 monoclonal antibody are incubated with a solution containing human fibrinogen at a concentration of between 500 and 800 mg/dl. It will be appreciated that the concentration of anti-CD34 Fab fragment will vary and that one of ordinary skill in the art could determine the optimal concentration without undue experimentation.
- the stent is added to the Fab/fibrin mixture and the fibrin activated by addition of concentrated thrombin (at a concentration of at least 1000 U/ml).
- the resulting polymerized fibrin mixture containing the Fab fragments incorporated directly into the matrix is pressed into a thin film (less than 0.12 cm) on the surface of the stent or synthetic graft.
- a thin film less than 0.12 cm
- any type of antibody or antibody fragment can be incorporated in this manner into a matrix solution prior to coating of a stent or synthetic graft.
- antibodies are covalently coupled to the matrix.
- the antibodies are tethered covalently to the matrix through the use of hetero- or homobifunctional linker molecules.
- the term “tethered” refers to a covalent coupling of the antibody to the matrix by a linker molecule.
- linker molecules in connection with the present invention typically involves covalently coupling the linker molecules to the matrix after it is adhered to the stent. After covalent coupling to the matrix, the linker molecules provide the matrix with a number of functionally active groups that can be used to covatently couple one or more types of antibody.
- FIG. 1 provides an illustration of coupling via a cross-linking molecule.
- An endothelial cell, 1 is an illustration of coupling via a cross-linking molecule.
- the linker molecules may be coupled to the matrix directly (i.e., through the carboxyl groups), or through well-known coupling chemistries, such as, esterification, amidation, and acylation.
- the linker molecule may be a di- or tri-amine functional compound that is coupled to the matrix through the direct formation of amide bonds, and provides amine-functional groups that are available for reaction with the antibodies.
- the linker molecule could be a polyamine functional polymer such as polyethyleneimine (PEI), polyallylamine (PALLA) or polyethyleneglycol (PEG).
- PEI polyethyleneimine
- PALLA polyallylamine
- PEG polyethyleneglycol
- a variety of PEG derivatives, e.g., mPEG-succinimidyl propionate or mPEG-N-hydroxysuccinimide, together with protocols for covalent coupling, are commercially available from Shearwater Corporation, Birmingham, Ala.
- Antibodies may be attached to C60O fullerene layers that have been deposited directly on the surface of the stent.
- Cross linking agents may be covalently attached to the fullerenes.
- the antibodies are then attached to the cross-linking agent, which in turn is attached to the stent.
- FIG. 2 provides an illustration of coupling by C60O.
- the endothelial cell, 2 . 01 is bound via a cell surface antigen, 2 . 02 , to an antibody, 2 . 03 , which in turn is bound, covalently or non-covalently to the matrix, 2 . 04 .
- the matrix, 2 . 04 is coupled covalently via C60O, 2 . 05 , to the stent, 2 . 06 .
- HUVEC will be prepared from human umbilical cords by the method of Jaffe (Jaffe, E. A. In “ Biology of Endothelial Cells ”, E. A. Jaffe, ed., Martinus-Nijhoff, The Hague (1984), incorporated herein by reference) and cultured in Medium 199 supplemented with 20% fetal calf serum (FCS), L-glutamine, antibiotics, 130 ug/ml heparin and 1.2 mg/ml endothelial cell growth supplement (Sigma-Aldrich, St. Louis, Mo.).
- FCS fetal calf serum
- L-glutamine L-glutamine
- antibiotics 130 ug/ml heparin
- 1.2 mg/ml endothelial cell growth supplement Sigma-Aldrich, St. Louis, Mo.
- Progenitor endothelial cells will be isolated from human peripheral blood by the method of Asahara et al. (Isolation of Putative progenitor endothelial cells for angiogenesis. Science 275:964-967). Monoclonal anti-CD34 antibodies will be coupled to magnetic beads and incubated with the leukocyte fraction of human whole blood. After incubation, bound cells will be eluted and cultured in M-199 containing 20% fetal bovine serum and bovine brain extract. (Clonetics, San Diego, Calif.). Cells will be characterized by fluorescent antibodies to CD45, CD34, CD31, Flk-1, Tie-2, and E- selectin.
- R stents produced by Orbus International B.V. will be incubated with human fibrinogen (Sigma, St. Louis, Mo.) 500-800 mg/ml together with Fab fragments of anti-CD34 monoclonal antibody and the fibrinogen will be polymerized by the addition of 1000 units/ml of thrombin.
- human fibrinogen Sigma, St. Louis, Mo.
- the fibrin will be compressed into a thin film less than 0.012 cm) against the R Stent.
- the R-Stent having the thin, fibrin film containing the Fab fragments will be washed three times with phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) at room temperature.
- PBS phosphate-buffered saline
- BSA bovine serum albumin
- R stents will be coated with mPEG-succinimidyl propionate (Shearwater Corporation, Birmingham, Ala.). The succinimidyl group will be reacted with the anti-CD34 monoclonal Fab fragments (Fab-PEG coated R stents) according to the manufacturer's instructions to form a stable amide linkage between the PEG derivative and the Fab fragment.
- mPEG-succinimidyl propionate Shearwater Corporation, Birmingham, Ala.
- the succinimidyl group will be reacted with the anti-CD34 monoclonal Fab fragments (Fab-PEG coated R stents) according to the manufacturer's instructions to form a stable amide linkage between the PEG derivative and the Fab fragment.
- the fibrin-anti-CD34 Fab coated R-stents or Fab-PEG coated R stents will be incubated with isolated HUEC or isolated progenitor endothelial cells at cellular concentrations of between 100,000 and 1,000,000 cells/ml in M199 containing 0.5% BSA at 37° C. in a 5% CO 2 humidified atmosphere. Prior to incubation with the stent, the HUVEC or progenitor endothelial cells will be labeled with [ 3 H]-thymidine for 24 hours.
- the stents After incubation of the labeled endothelial cells with the stents coated with fibrin and Fab anti-CD34 for between 4 and 72 hours, the stents will be removed from the solution and washed 5 times with M199 containing 0.5% BSA. Bound endothelial cells will be removed by trypsinization and binding of labeled endotheltal cells to the stents will be assessed by scintillation counting of [ 3 H]-thynidine. As negative control, stents coated with fibrin alone or uncoated stents will be incubated with [ 3 H]-thymidine-labeled endothelial cells. Results will be evaluated statistically using a t-test to determine differential binding. Stents coated with fibrin which incorporate monoclonal anti-CD34 Fab fragments will show significantly increased binding of endothelial cells as compared with uncoated stents.
- R stents coated with fibrin that incorporates anti-CD34 Fab fragments will be incubated with HUVEC or progenitor endothelial cells for between 4 and 72 hours in M199 containing 0.5% BSA. After incubation of the stents with the HUVEC or progenitor endothelial cells, the stents will be washed 5 times with M199 containing 0.5% BSA and then incubated with [ 3 H]-thymidine. [ 3 H]-thymidine incorporation will be assessed in washed and harvested HUVEC or progenitor endothelial cells (cells will be harvested with trypsin).
- Proliferation of HUVEC or progenitor endothelial cells on fibrin-coated stents will be compared with endothelial cell proliferation in standard microtiter dishes. Proliferation of HUVEC or progenitor endothelial cells on fibrin-coated stents will be equal to or greater than proliferation of endothelial cells in microtiter dishes
- BALB/c mice will be immunized, intraperitoneally 3-4 times at 2-4 weekly intervals, with 1.5 ⁇ 10 6 HUVEC in PBS or 1.5 ⁇ 10 5 progenitor endothelial cells and challenged 3 days prior to spleen-cell removal with 1.5 ⁇ 10 6 HUVEC or 1.5 ⁇ 10 6 progenitor endothelial cells.
- a spleen-cell suspension will be prepared, fused with the myeloma NS1/1 AG4.1 and hybridomas grown up and cloned.
- 10% endothelial-cell conditioned medium (HVEC) will be included in culture media.
- hybridoma culture supernatants will be tested for reactivity with HUVEC or progenitor endothelial cells by immunofluorescence flow cytometry (FACS). Briefly, HUVAC (1.5 ⁇ 10 4 ) or progenitor endothelial cells (1.5 ⁇ 10 4 ) will be incubated (30 min., 4° C.) with undiluted hybridoma supernatant, washed and incubated with fluorescein-isothiocyanate (FITC)-sheep F(ab′) 2 anti-mouse Ig(100 ug/mi). Following final washing, the endothelial cells will be examined for monoclonal antibody binding by FACS analysis.
- FITC fluorescein-isothiocyanate
- Positive hybridoma supernatants will be screened on the human melanoma cell line MM-170 to eliminate non-endothelial specific mAbs. Endothelial specificity will be further confirmed by screening of monoclonal antibodies on a panel of human tumor cell lines as well as human lymphocytes, monocytes, neutrophils, red cells and platelets.
- Implantation of antibody-covered stents will be performed in juvenile Yorkshire pigs weighing between 25 and 30 kg. Animal care will comply with the “Guide for the Care and Use of Laboratory Animals” (NIH publication No. 80-23, revised 1985). After an overnight fast, animals will be sedated with ketamine hydrochloride (20 mg/kg). Following the induction of anesthesia with thiopental (12 mg/kg) the animals will be intubated and connected to a ventilator that will administer a mixture of oxygen and nitrous oxide (1:2 [vol/vol]).
- Antibiotic prophylaxis will be provided by an intramuscular injection of 1,000 mg of a mixture of procaine penicillin-G and benzathine penicillin-G (streptomycin).
- an arteriotomy of the left carotid artery will be performed and a 9F-introducer sheath will be placed in the left carotid artery. All animals will be given 7,500 IU of heparin sodium and 100 mg of acetylsalicylic acid intravenously. Additional 2,500 IU boluses of heparin will be administered periodically throughout the procedure in order to maintain an activated clotting time above 300 seconds. An 8F guiding catheter will be introduced through the carotid sheath and passed to the origin of the iliac artery. Angiography will be performed after the administration of 1 mg of isosorbide dinitrate and images will be analyzed using a quantitative coronary angiography system.
- a 3F-embolectomy catheter will be inserted into the common femoral artery, and passed distal to the segment selected for stent implantation.
- the embolectomy balloon will be inflated to a size 0.5 mm larger than the arterial segment and withdrawn twice to denude the vessel.
- a fibrin-coated stent incorporating an Fab fragment of a monoclonal antibody will be inserted through the guiding catheter and deployed in the denuded segment of the femoral artery.
- Animals will be sacrificed both at 3 days and at eight weeks after stent implantation. The animal will first be sedated and anesthetized as described above.
- the stented femoral segments will be explanted and then placed in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.2 at 4° C. for 48 h.
- a rectangular section of the vessel wall will be removed for further processing for electron microscopic evaluation of surface coverage of endothelial cells.
- This portion of the stented vessel will be placed in 0.15 cacodylate buffer and further fixed with 2.5% glutaraldehyde in 0.15 M cacodylate.
- the tissue will then be post-fixed with 0.1 M cacodylate buffer containing 1% OsO 4 and 50 mM ferricyanide (K 3 [Fe(CN) 6 ]), and further processed.
- Embedded arterial segments with the stent in place will be cut into sections 3 to 5 ⁇ m thick on a motor-driven rotary microtome (H- 350 , Microm GmbH, Kunststoff, Germany) using stainless steel disposable knives.
- H- 350 motor-driven rotary microtome
- sections will be stretched on a hot plate at 40° C. using a mixture of 60% 2-butoxyethanol and 10% ethanol in water. Sections will be covered by a plastic film, excess butoxyethanol-ethanol mixture removed and the slides will be left overnight to dry in a 40° C. oven.
- Sections will then be deplasticized in a solution of equal volumes of xylene-chloroform for 30 to 60 minutes. Standard staining procedures for light microscopy will then be performed on the prepared sections.
- Statistics Data will be presented as the mean ⁇ standard error of the mean (SD) of the independent experiments. Statistical significance will be determined by one way analysis of variance (ANOVA) and Fisher's PLSD test (StatView 4.01; Brain Power, Inc., Calabasas, Calif.) For data of treated and untreated segments of femoral arteries, a paired t test (StatView 4.01) will be used. A p value of ⁇ 0.05 will be considered a statistically significant difference between the means. Animals treated with a stent incorporating an anti-porcine endothelial cell monoclonal Fab fragment will show increased endothelial cell coverage and significantly reduced restenosis as compared with controls having an uncoated stent implanted.
- Porcine progenitor endothelial cells will be isolated from pig peripheral blood by the method of Asahara et al. (Isolation of Putative progenitor endothelial cells for angiogenesis. Science 275:964-967). Monoclonal anti-CD34 antibodies will be coupled to magnetic beads and incubated with the leukocyte fraction of pig whole blood. After incubation, bound cells will be eluted and cultured in M-199 containing 20% fetal bovine serum and bovine brain extract. (Clonetics, San Diego, Calif.). Cells will be characterized by fluorescent antibodies to CD45, CD34, CD31, Flk-1, Tie-2, and E- selectin.
- purified porcine progenitor endothelial cells will be transfected with vascular endothelial growth factor (VEGF) using an adenovirus vector expressing the VEGF cDNA according to the methods of Rosenaart et al. (Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230(4):466-470 (1999), incorporated herein by reference).
- VEGF vascular endothelial growth factor
- the transfected purified porcine progenitor cells expressing VEGF will be infused into the porcine femoral artery model after balloon injury and stent implantation as described in Example 4 using a double-balloon chamber infusion catheter (Cordis Corp) which isolates the stented portion of the femoral artery. Restenosis will be compared in balloon angioplasty stent-treated pigs infused with VEGF-transfected porcine progenitor cells as compared with pigs infused with un-transfected porcine progenitor endothelial cells. Expression of VEGF in the re-infused porcine progenitor endothelial cells will result in a decreased incidence and severity of restenosis in the anti-CD34 coated stents.
- Stent Preparation stents will be made from 316 L stainless steel and will be cleaned and passivated by first washing in an anionic detergent in an ultrasonic cleaner and then soaked in hot nitric acid with agitation, followed by a final deionized water rinse.
- Derivatized stents will be prepared as follows—stents will be dipped into a 2% mixture of N-(2-aminoethyl-3-aminopropyl) trimethoxysilane in 95% ethanol for three minutes, removed, air dried at room temperature and then cured for 10 minutes at 110° C.
- Polyethylene glycol (PEG) Spacer Coupling Derivatized stents will be placed in 100ml of 0.1 M MES buffer containing 10 mM Dicarboxymethyl-PEG and 500 mg of EDC added and incubated at 25° C. with constant stirring for two hours.
- Tethered Antibody Antibodies to endothelial cells will be immobilized to the PEG functionalized stents in a one-step carbodiimide coupling reaction by immersing the stents into 150 ml of 0.1 M MES buffer (pH 4.5) into which 1.0 mg of murine anti-CD34 IgG 1 antibody is dissolved and incubated at 25° C. for two hours. Stents will be removed from the solution and rinsed five times with 50 ml of phosphate buffered saline (pH 7.2) with 0.02% Tween 20.
- Reagents include: N-(2-aminoethyl-3-aminopropyl)trimethoxysilane (Degussa-Huls); MES buffer—morpholine ethane sulfonic acid buffer (Sigma, St. Louis, Mo.); EDC—1-ethyl-3-(3-dimethylaminopropyl) carbodiinde (Sigma, St. Louis, Mo.); Dicarboxymethyl-PEG -Dicarboxymethyl-poly(ethylene glycol) [MW 3400] (Shearwater, Huntsville, Ala).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Surgery (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Materials Engineering (AREA)
- Composite Materials (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Developmental Biology & Embryology (AREA)
Abstract
This invention provides compositions and methods for producing a medical device coated with a matrix and an antibody which reacts with an endothelial cell antigen. The matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol. In another embodiment, the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin, amorphous carbon. In a third embodiment, the matrix may be composed of fillerenes. The fullerenes range from about C60 to about C100. The medical device may be a stent or a synthetic graft. The antibodies promote adherence of eadothelial cells on the medical device. The antibodies may be mixed with the matrix or covalently tethered through a linker molecule to the matrix. Following adherence to the medical device, the endothelial cells differentiate and proliferate on the medical device. The antibodies may be different types of monoclonal antibodies. Methods of preparing such composition and methods of treating a mammal with atherosclerosis or other types of vessel obstruction are disclosed. By facilitating adherence of endothelial cells to the surface of the medical device, the methods and compositions of this invention will decrease the incidence of restenosis as well as other thromboembolic complications resulting from implantation of medical devices.
Description
- This application claims the benefit of U.S. Provisional Application Nos. 60/189,674 filed Mar. 15, 2000 and 60/201,789 filed May 4, 2000.
- The present invention relates to the field of medical devices implanted in vessels within the body. More particularly, the present invention relates to stents or synthetic grafts implanted in blood vessels that incorporate a matrix which promotes adherence of endothelial cells to the stent or synthetic graft.
- Atherosclerosis is one of the leading causes of death and disability in the world. Atherosclerosis involves the deposition of fatty plaques on the lumenal surface of arteries. The deposition of fatty plaques on the lumenal surface of the artery causes narrowing of the cross-sectional area of the artery. Ultimately, this deposition blocks blood flow distal to the lesion causing ischemic damage to the tissues supplied by the artery.
- Coronary arteries supply the heart with blood. Coronary artery atherosclerosis disease (CAD) is the most common, serious, chronic, life-threatening illness in the United States, affecting more than 11 million persons. The social and economic costs of coronary atherosclerosis vastly exceed that of most other diseases. Narrowing of the coronary artery lumen causes destruction of heart muscle resulting first in angina, followed by myocardial infarction and finally death. There are over 1.5 million myocardial infarctions in the United States each year. Six hundred thousand (or 40%) of those patients suffer an acute myocardial infarction and more than three hundred thousand of those patients die before reaching the hospital. (Harrison's Principles of Internal Medicine, 14th Edition, 1998).
- CAD can be treated using percutaneous translumenal coronary balloon angioplasty (PTCA). More than 400,000 PTCA procedures are performed each year in the United States. In PTCA, a balloon catheter is inserted into a peripheral artery and threaded through the arterial system into the blocked coronary artery. The balloon is then inflated, the artery stretched, and the obstructing fatty plaque flattened, thereby increasing the cross-sectional flow of blood through the affected artery. The therapy, however, does not usually result in a permanent opening of the affected coronary artery. As many as 50% of the patients who are treated by PTCA require a repeat procedure within six months to correct a re-narrowing of the coronary artery. Medically, this re-narrowing of the artery after treatment by PTCA is called restenosis. Acutely, restenosis involves recoil and shrinkage of the vessel. Subsequently, recoil and shrinkage of the vessel are followed by proliferation of medial smooth muscle cells in response to injury of the artery from PTCA. In part, proliferation of smooth muscle cells is mediated by release of various inflammatory factors from the injured area including thromboxane A2, platelet derived growth factor (PDGF) and fibroblast growth factor FGF). A number of different techniques have been used to overcome the problem of restenosis, including treatment of patients with various pharmacological agents or mechanically holding the artery open with a stent. (Harrison's Principles of Internal Medicine, 14th Edition, 1998).
- Of the various procedures used to overcome restenosis, stents have proven to be the most effective. Stents are metal scaffolds that are positioned in the diseased vessel segment to create a normal vessel lumen. Placement of the stent in the affected arterial segment prevents recoil and subsequent closing of the artery. Stents can also prevent local dissection of the artery along the medial layer of the artery. By maintaining a larger lumen than that created using PTCA alone, stents reduce restenosis by as much as 30%. Despite their success, stents have not eliminated restenosis entirely. (Suryapranata et al. 1998. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 97:2502-2502).
- Narrowing of the arteries can occur in vessels other than the coronary arteries, including the aortoiliac, infrainguinal, distal profinda femoris, distal popliteal, tibial, subclavian and mesenteric arteries. The prevalence of peripheral artery atherosclerosis disease (PAD) depends on the particular anatomic site affected as well as the criteria used for diagnosis of the occlusion. Traditionally, physicians have used the test of intermittent claudication to determine whether PAD is present. However, this measure may vastly underestimate the actual incidence of the disease in the population. Rates of PAD appear to vary with age, with an increasing incidence of PAD in older individuals. Data from the National Hospital Discharge Survey estimate that every year, 55,000 men and 44,000 women had a first-listed diagnosis of chronic PAD and 60,000 men and 50,000 women had a first-listed diagnosis of acute PAD. Ninety-one percent of the acute PAD cases involved the lower extremity. The prevalence of comorbid CAD in patients with PAD can exceed 50%. In addition, there is an increased prevalence of cerebrovascular disease among patients with PAD.
- PAD can be treated using percutaneous translumenal balloon angioplasty (PTA). The use of stents in conjunction with PTA decreases the incidence of restenosis. However, the post-operative results obtained with medical devices such as stents do not match the results obtained using standard operative revascularization procedures, i.e., those using a venous or prosthetic bypass material. (Principles of Surgery, Schwartz et al. eds., Chapter 20, Arterial Disease, 7th Edition, McGraw-Hill Health Professions Division, New York 1999).
- Preferably, PAD is treated using bypass procedures where the blocked section of the artery is bypassed using a graft. (Principles of Surgery, Schwartz et al. eds., Chapter 20, Arteral Disease, 7th Edition, McGraw-Hill Health Professions Division, New York 1999). The graft can consist of an autologous venous segment such as the saphenous vein or a synthetic graft such as one made of polyester, polytetrafluoroethylene (PTFE), or expanded polytetrafluoroethylene (ePTFE). The post-operative patency rates depend on a number of different factors, including the lumenal dimensions of the bypass graft, the type of synthetic material used for the graft and the site of outflow. Restenosis and thrombosis, however, remain significant problems even with the use of bypass grafts. For example, the patency of infrainguinal bypass procedures at 3 years using an ePTFE bypass graft is 54% for a femoral-popliteal bypass and only 12% for a femoral-tibial bypass.
- Consequently, there is a significant need to improve the performance of both stents and synthetic bypass grafts in order to further reduce the morbidity and mortality of CAD and PAD.
- With stents, the approach has been to coat the stents with various anti-thrombotic or anti-restenotic agents in order to reduce thrombosis and restenosis. For example, impregnating stents with radioactive material appears to inhibit restenosis by inhibiting migration and proliferation of myofibroblasts. (U.S. Pat. Nos. 5,059,166, 5,199,939 and 5,302,168). Irradiation of the treated vessel can pose safety problems for the physician and the patient. In addition, irradiation does not permit uniform treatment of the affected vessel.
- Alternatively, stents have also been coated with chemical agents such as heparin or phosphorylcholine, both of which appear to decrease thrombosis and restenosis. Although heparin and phosphbrylcholine appear to markedly reduce restenosis in animal models in the short term, treatment with these agents appears to have no long-term effect on preventing restenosis. Additionally, heparin can induce thrombocytopenia, leading to severe thromboembolic complications such as stroke. Nonetheless, it is not feasible to load stents with sufficient therapeutically effective quantities of either heparin or phosphorylcholine to make treatment of restenosis in this manner practical.
- Synthetic grafts have been treated in a variety of ways to reduce postoperative restenosis and thrombosis. (Bos et al. 1998. Small-Diameter Vascular Graft Prostheses:Current Status Achives Physio. Biochem. 106:100-115). For example, composites of polyurethane such as meshed polycabonate urethane have been reported to reduce restenosis as compared with ePTFE grafts. The surface of the graft has also been modified using radiofrequency glow discharge to add polyterephalate to the ePTFE graft. Synthetic grafts have also been impregnated with biomolecules such as collagen. However, none of these approaches has significantly reduced the incidence of thrombosis or restenosis over an extended period of time.
- Because endothelial cells possess certain intrinsic characteristics such as cell regulatory molecules that decrease the incidence of thrombosis or restenosis, stimulating the development of an endothelial cell monolayer on the surface of stents or synthetic grafts may prevent both restenosis and thrombosis. (Belle et al. 1997. Stent Endothelialization. Circulation 95:438-448; Bos et al. 1998. Small-Diameter Vascular Graft Prostheses:Current Status Archives Physio. Biochem. 106:100-115).
- Endothelial cells have been deposited on the surface of stents by local delivery of vascular endothelial growth factor (VEGF), an endothelial cell mitogen, after implantation of the stent. (Belle et al. 1997. Stent Endothelialization. Circulation 95:438-448.). Because the application of VEGF can have systemic as well as local effects, this form of treatment may be unreliable.
- Synthetic grafts have also been seeded with endothelial cells, but the clinical results with endothelial seeding have been generally poor, i.e., low post-operative patency rates (Lio et al. 1998. New concepts and Materials in Microvascular Grafting: Prosthetic Graft Endothelial Cell Seeding and Gene Therapy. Microsurgery 18:263-256).
- Accordingly, there is a need for development of new methods and compositions for coating medical devices, including stents and synthetic grafts, with endothelial cells. This type of coating will not only prevent restenosis, but also thromboembolic complications resulting from stent implantation. Methods and compositions that provide such improvement will eliminate the drawbacks of previous technology and have a significant positive impact on the morbidity and mortality associated with CAD and PAD. It is the object of this invention to prepare stents and synthetic grafts coated in such a manner as to stimulate adherence of endothelial cells to a medical device such as a stent or synthetic graft.
- The invention provides methods and compositions for coating medical devices with a matrix that promotes adherence of endothelial cells to a medical device. The matrix incorporates antibodies that stimulate adherence of endothelial cells to the surface of the medical device.
- As used herein, “medical device” refers to a device that is introduced temporarily or permanently into a mammal for the prophylaxis or therapy of a medical condition. These devices include any that are introduced subcutaneously, percutaneously or surgically to rest within an organ, tissue or lumen. Medical devices may include stents, covered stents such as those covered with polytetrafluoroethylene (PTFE), or expanded polytetrafluoroethylene (ePTFE), synthetic grafts, artificial heart valves, artificial hearts and fixtures to connect the prosthetic organ to the vascular circulation, venous valves, abdominal aortic aneurysm (AAA) grafts, inferior venal caval filters, permanent drug infision catheters, embolic coils, embolic materials used in vascular embolization (e.g., PVA foams), and vascular sutures.
- Coating of the medical device with the compositions and methods of this invention may stimulate the development of an endothelial cell layer on the surface of the medical device, thereby preventing restenosis as well as other thromboembolic complications that result from implantation of the medical device.
- Synthetic grafts and stents can be used for treating CAD or PAD. A stent or synthetic graft may be coated with a matrix incorporating antibodies that stimulate adherence of circulating progenitor endothelial cells to the medical device. The antibodies may comprise monoclonal antibodies reactive with endothelial cell surface antigens such as CD34, an antigen expressed on the surface of progenitor endothelial cells. Fab fragments of the monoclonal antibody may be used. In another embodiment, monoclonal antibodies directed against other endothelial surface antigens such as KDP, or Tie-2, may also be used. In one embodiment, a single type of antibody that reacts with one antigen may be used. Alternatively, a plurality of different antibodies directed against different endothelial cell surface antigens may be mixed together and added to the matrix.
- The matrix coating the medical device may be composed of synthetic material, such as polyurethane, poly-L-lactic acid, cellulose ester or polyethylene glycol. In another embodiment, the matrix is composed of naturally occurring materials, such as collagen, fibrin, elastin or amorphous carbon. The matrix may comprise several layers with a first layer being composed of synthetic or naturally occurring materials and a second layer composed of antibodies. The layers may be ordered sequentially, with the first layer directly in contact with the stent or synthetic graft surface and the second layer having one surface in contact with the first layer and the opposite surface in contact with the vessel lumen.
- In a third embodiment, the matrix may comprise fullerenes, where the fullerenes range from about C60 to about C100. The fullerenes may also be arranged as nanotubes, that incorporate molecules or proteins. The fullerenes matrix may also be mixed with PTFE or ePTFE, or antibodies. Alternatively, the PTFE or ePTFE may be layered first on the medical device followed by a second layer of fullerenes.
- The matrix may be noncovalently or covalently attached to the medical device. Antibodies may be covalently attached to the matrix using hetero- or homobifunctional cross-linking reagents.
- Methods of treatment of atherosclerosis are also provided. The artery may be the either a coronary artery or a peripheral artery such as the femoral artery.
-
FIG. 1 shows an antibody tethered covalently to the matrix by a cross-linking molecule. -
FIG. 2 shows a diagram of the C60O molecule anchoring the matrix. - Overview
- The present invention provides methods and compositions that involve coating a medical device such as a stent or synthetic graft with a matrix which is then used to coat the medical device. In one embodiment, the matrix incorporates a therapeutically effective amount of at least one type of antibody that promotes adherence of endothelial cells to the medical device. Following adherence, the endothelial cells differentiate and proliferate on the surface of the matrix. The presence of endothelial cells on the medical device reduces the occurrence of restenosis and thrombosis after medical device implantation into a vessel.
- As used herein, the term “antibody” refers to one type of monoclonal or polyclonal antibody, where the monoclonal or polydonal antibody binds to one antigen or a functional equivalent of that antigen. The term antibody encompasses any fragment of an antibody such as Fab, F(ab′)2 or Fc fragments. (An antibody encompasses a plurality of individual antibody molecules equal to 6.022×1023 molecules per mole of antibody).
- As used herein, a “therapeutically effective amount of the antibody” means the amount of an antibody that promotes adherence of endothelial cells to the medical device. The amount of an antibody needed to practice the claimed invention varies with the nature of the antibody used. For example, the amount of an antibody used will depend on the binding constant between the antibody and the antigen against which it reacts. It is well known to those of ordinary skill in the art how to determine therapeutically effective amounts of an antibody to use with a particular antigen.
- As used herein, “medical device” refers to a device that is introduced temporarily or permanently into a mammal for the prophylaxis or therapy of a medical condition. These devices include any that are introduced subcutaneously, percutaneously or surgically to rest within an organ, tissue or lumen. Medical devices may include, stents, covered stents such as those covered with PTFE, or ePTFE, synthetic grafts, artificial heart valves, artificial hearts and fixtures to connect the prosthetic organ to the vascular circulation, venous valves, abdominal aortic aneurysm (AAA) grafts, inferior venal caval filters, permanent drug infusion catheters, embolic coils, embolic materials used in vascular embolization (e.g., PVA foams), and vascular sutures,
- As used herein, “restenosis” refers to the accumulation of a layer of smooth muscle cells and matrix protein in the intima of an arterial wall. Vessels may become obstructed because of restenosis. After PTCA or PTA, smooth muscle cells from the media and adventitia, which are not normally present in the intima, proliferate and migrate to the intima and secrete proteins, forming an accumulation of smooth muscle cells and matrix protein within the intima. This accumulation causes a narrowing of the lumen of the artery, reducing blood flow distal to the narrowing. As used herein, “inhibition of restenosis” refers to the inhibition of migration and proliferation of smooth muscle cells accompanied by prevention of protein secretion so as to prevent restenosis and the complications arising therefrom.
- The subjects that can be treated using the methods and compositions of this invention may be a mammal, or more specifically, a human, dog cat, pig, rodent or monkey.
- The methods of the present invention may be practiced in vivo or in vitro.
- The term “endothelial cell” refers to endothelial cells at any developmental stage, from progenitor to mature. Fully differentiated endothelial cells may be isolated from an artery or vein such as a human umbilical vein, while progenitor endothelial cells are isolated from peripheral blood or bone marrow. The endothelial cells are bound to the medical devices by incubation of the endothelial cells with a medical device coated with the matrix that incorporates an antibody or other agent that adheres to endothelial cells.
- The methods of this invention may be practiced on any artery or vein. Included within the scope of this invention is atherosclerosis of any artery including coronary, infrainguinal, aortoiliac, subclavian, mesenteric and renal arteries. Other types of vessel obstructions, such as those resulting from a dissecting aneurysm are also encompassed by the invention.
- The medical device may be coated with endothelial cells after insertion into a vessel. Alternatively, the medical device is coated with the endothelial cells before insertion of the medical device. In either case, the presence of endothelial cells on the lumenal surface of the medical device inhibits or prevents restenosis and thrombosis.
- Endothelial Cells
- Human umbilical vein endothelial cells (HUVEC) are obtained from umbilical cords according to the methods of Jaffe, et al., J. Clin. Invest., 52:2745-2757, 1973, incorporated herein by reference. Briefly, cells are stripped from the blood vessel walls by treatment with collagenase and cultured in gelatin-coated tissue culture flasks in M199 medium containing 10% low endotoxin fetal calf serum, 90 ug/ml preservative-free porcine heparin, 20 ug/ml endothelial cell growth supplement ECGS), glutamine and antibodies.
- Progenitor endothelial cells are isolated from human peripheral blood according to the methods of Asahara et al. (Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997, incorporated herein by reference). Magnetic beads coated with antibody to CD34 are incubated with human peripheral blood. After incubation, bound cells are eluted and can be cultured in M-199 containing 20% fetal bovine serum and bovine brain extract. (Clonetics, San Diego, Calif.). Cells are characterized by fluorescent antibodies to CD45, CD34, CD31, Flk-1, Tie-2, and E-selectin.
- Endothelial cells are transfected with any mammalian expression vectors that contains any cloned genes encoding proteins such as platelet derived growth factor (PDGF), fibroblast growth factor (FGF), or nitric oxide synthase (NOS) using conventional methods. (See, for example, mammalian expression vectors and transfection kits commercially available from Stratagene, San Diego, Calif.). For example, purified porcine progenitor endothelial cells are transfected with vascular endothelial growth factor (VEGF) using an adenoviral expression vector expressing the VEGF cDNA according to the methods of Rosengart et al. (Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA Ann. Sur. 230(4):466-470 (1999), incorporated herein by reference).
- Antibodies
- Monoclonal antibodies useful in the method of the invention may be produced according to the standard techniques of Kobler and Milstein (Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 265:495-497, 1975, incorporated herein by reference). Endothelial cells can be used as the immunogen to produce monoclonal antibodies directed against endothelial cell surface antigens.
- Monoclonal antibodies directed against endothelial cells are prepared by injecting HUVEC or purified progenitor endothelial cells into a mouse or rat. After a sufficient time, the mouse is sacrificed and spleen cells are obtained. The spleen cells are immortalized by fusing them with myeloma cells or with lymphoma cells, generally in the presence of a non-ionic detergent, for example, polyethylene glycol. The resulting cells, which include the fused hybridomas, are allowed to grow in a selective medium, such as HAT-medium, and the surviving cells are grown in such medium using limiting dilution conditions. The cells are grown in a suitable container, e.g., microtiter wells, and the supernatant is screened for monoclonal antibodies having the desired specificity, ie., reactivity with endothelial cell antigens.
- Various techniques exist for enhancing yields of monoclonal antibodies such as injection of the hybridoma cells into the peritoneal cavity of a mammalian host which accepts the cells and then harvesting the ascites fluid. Where an insufficient amount of monoclonal antibody collects in the ascites fluid, the antibody is harvested from the blood of the host. Various conventional ways exist for isolation and purification of monoclonal antibodies so as to free the monoclonal antibodies from other proteins and other contaminants.
- Also included within the scope of the invention are useful binding fragments of anti-endothelial cell monoclonal antibodies such as the Fab, F(ab′)2, or Fc fragments of these monoclonal antibodies. The antibody fragments are obtained by conventional techniques. For example, useful binding fragments may be prepared by peptidase digestion of the antibody using papain or pepsin.
- Antibodies of the invention are directed to an antibody of the IgG class from a murine source; however, this is not meant to be a limitation. The above antibody and those antibodies having functional equivalency with the above antibody, whether from a murine source, mammalian source including human, or other sources, or combinations thereof are included within the scope of this invention, as well as other classes such as IgM, IgA, IgE, and the like, including isotypes within such classes. In the case of antibodies, the term “functional equivalency” means that two different antibodies each bind to the same antigenic site on an antigen, in other words, the antibodies compete for binding to the same antigen. The antigen may be on the same or different molecule.
- In one embodiment, monoclonal antibodies reacting with the endothelial cell surface antigen CD34 are used. Anti-CD34 monoclonal antibodies attached to a solid support have been shown to capture progenitor endothelial cells from human peripheral blood. After capture, these progenitor cells are capable of differentiating into endothelial cells. (Asahara et al. 1997. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275: 964-967.) Hybridomas producing monoclonal antibodies directed against CD34 can be obtained from the American Type Tissue Collection. (Rockville, Md). In another embodiment, monoclonal antibodies reactive with endothelial cell surface antigens Flk-1 or Tie-2 are used.
- Polyclonal antibodies reactive against endothelial cells isolated from the same species as the one receiving the medical device implant may also be used.
- Stent
- The term “stent” herein means any medical device which when inserted into the lumen of a vessel expands the cross-sectional lumen of a vessel. The term “stent” includes covered stents such as those covered with PTFE or ePTFE. In one embodiment, this includes stents delivered percutaneously to treat coronary artery occlusions or to seal dissections or aneurysms of the splenic, carotid, iliac and popliteal vessels. In another embodiment, the stent is delivered into a venous vessel. The stent can be composed of polymeric or metallic structural elements onto which the matrix is applied or the stent can be a composite of the matrix intermixed with a polymer. For example, a deformable metal wire stent can be used, such as that disclosed in U.S. Pat. No. 4,886,062 to Wiktor, incorporated herein by reference. A self-expanding stent of resilient polymeric material such as that disclosed in published international patent application WO91/12779 “Intraluminal Drug Eluting Prosthesis”, incorporated herein by reference, can also be used. Stents may also be manufactured using stainless steel, polymers, nickel-titanium, tantalum, gold, platinum-irdium, or Elgiloy and MP35N and other ferrous materials. Stents are delivered through the body lumen on a catheter to the treatment site where the stent is released from the catheter, allowing the stent to expand into direct contact with the lumenal wall of the vessel. It will be apparent to those skilled in the art that other self-expanding stent designs (such as resilient metal stent designs) could be used with the antibodies and matrices of this invention.
- Synthetic Graft
- The term “synthetic graft” means any artificial prosthesis having biocompatible characteristics. In one embodiment this includes synthetic grafts made of Dacron (polyethylene terephthalate, PET) or Teflon (ePTFE). In another embodiment, synthetic grafts are composed of polyurethane. In yet a third embodiment, a synthetic graft is composed of an inner layer of meshed polycarbonate urethane and an outer layer of meshed Dacron. It will be apparent to those skilled in the art that any biocompatible synthetic graft can be used with the antibodies and matrices of this invention. (Bos et al. 1998. Small-Diameter Vascular Prostheses: Current Status. Archives Physio Biochem. 106:100-115, incorporated herein by reference). Synthetic grafts can be used for end-to-end anastomosis of vessels or for bypass of a diseased vessel segment.
- Matrix
- (A) Synthetic Materials—The matrix that is used to coat the stent or synthetic graft may be selected from synthetic materials such as polyurethane, segmented polyurethane-urea/heparin, poly-L-lactic acid, cellulose ester or polyethylene glycol.
- (B) Naturally Occurring Material—The matrix may be selected from naturally occurring substances such as collagen, laminin, heparin, fibrin, cellulose or carbon. A primary requirement for the matrix is that it be sufficiently elastic and flexible to remain unruptured on the exposed surfaces of the stent or synthetic graft.
- (C) Fullerenes—The matrix may also comprise a fullerenes (the term “fullerenes” encompasses a plurality of fullerenes molecules). Fullerenes are carbon-cage molecules. The number of carbon (C) molecules in a fullerenes species varies from about C60 to about C100. Fullerenes are produced by high temperature reactions of elemental carbon or of carbon-containing species by processes well known to those skilled in the art; for example, by laser vaporization of carbon, heating carbon in an electric arc or burning of hydrocarbons in sooting flames. (U.S. Pat. No. 5,292,813, to Patel et al., incorporated herein by reference; U.S. Pat. No. 5,558,903 to Bhushan et al., incorporated herein by reference). In each case, a carbonaceous deposit or soot is produced. From this soot, various fullerenes are obtained by extraction with appropriate solvents, such as toluene. The fillerenes are separated by known methods, in particular by high performance liquid chromatography (HPLC). Fullerenes may be synthesized or obtained commercially from Dynamic Enterprises, Ltd., Berkshire, England or Southern Chemical Group, LLC, Tucker, Ga.
- Fullerenes may be deposited on surfaces in a variety of different ways, including, sublimation, laser vaporization, sputtering, ion beam, spray coating, dip coating, roll-on or brush coating as disclosed in U.S. Pat. No. 5,558,903.
- An important feature of fullerenes is their ability to form “activated carbon.” The fullerene electronic structure is a system of overlapping pi-orbitals, such that a multitude of bonding electrons are cooperatively presented around the surface of the molecule. (Chemical and Engineering News. Apr. 8, 1991, page 59, incorporated herein by reference). As forms of activated carbon, fullerenes exhibit substantial van der Waals forces for weak interactions. The adsorptive nature of the fullerenes surface may lend itself to additional modifications for the purpose of directing specific cell membrane interactions. For example, specific molecules that possess chemical properties that selectively bind to cell membranes of particular cell types or to particular components of cell membranes, e.g., lectins or antibodies, can be adsorbed to the fullerene surface. The fullerene surface may also be chemically modified to present specifically reactive groups to the cell membrane, e.g., oxidants or reductants. Attachment of different molecules to the fullerene surface may be manipulated to create surfaces that selectively bind various cell types, e.g., epithelial cells, fibroblasts, primary explants, or T-cell subpopulations. U.S. Pat. No. 5,310,669 to Richmond et al., incorporated herein by reference; Stephen R. Wilson, Biological Aspects of Fullerenes, Fullerenes:Chemistry, Physics and Technology, Kadish et al. eds., John Wiley & Sons, NY 2000, incorporated herein by reference.
- Fullerenes may also form nanotubes that incorporate other atoms or molecules. (Liu et al. Science 280:1253-1256 (1998), incorporated herein by reference). The synthesis and preparation of carbon nanotubes is well known in the art. (U.S. Pat. No. 5,753,088 to Olk et al., and U.S. Pat. No. 5,641,466 to Ebbsen et al., both incorporated herein by reference). Molecules such as proteins may also be incorporated inside carbon nanotubes. For example, nanotubes may be filled with the enzymes, e.g., Zn2Cd2-metallothionein, cytochromes C and C3, and beta-lactamase after cutting the ends of the nanotube. (Davis et al. Inorianica Chim. Acta 272:261 (1998); Cook et al. Full Sci. Tech. 5(4):695 (1997), both incorporated herein by reference).
- Three dimensional fullerene structures may also be used. U.S. Pat. No. 5,338,571 to Mirkin et al., incorporated herein by reference, discloses three-dimensional, multilayer fullerene structures that are formed on a substrate surface by (i) chemically modifying fillerenes to provide a bond-forming species; (ii) chemically treating a surface of the substrate to provide a bond-forming species effective to covalently bond with the bond-forming species of the fillerenes in solution; and, (iii) contacting a solution of modified fullerenes with the treated substrate surface to form a fullerene layer covalently bonded to the treated substrate surface.
- (D) Application of the Matrix to the Medical Device
- The matrix should adhere tightly to the surface of the stent or synthetic graft. Preferably, this is accomplished by applying the matrix in successive thin layers. Each layer of matrix may incorporate the antibodies. Alternatively, antibodies may be applied only to the layer in direct contact with the vessel lumen. Different types of matrices may be applied successively in succeeding layers. The antibodies may be covalently or noncovalently coated on the matrix after application of the matrix to the stent.
- In order to coat a medical device such as a stent, the stent is dipped or sprayed with a liquid solution of the matrix of moderate viscosity. After each layer is applied, the stent is dried before application of the next layer. In one embodiment, a thin, paint-like matrix coating does not exceed an overall thickness of 100 microns.
- For example, a suitable matrix coating solution is prepared by dissolving 480 milligrams (mg) of a drug carrier, such as poly-D, L-lactid (available as R203 of Boehringer Inc., Ingetheim, Germany) in 3 milliliters (ml) of chloroform under aseptic conditions. In principle, however, any biodegradable (or non-biodegradable) matrix that is blood-and tissue-compatible (biocompatible) and can be dissolved, dispersed or emulsified may be used as the matrix if, after application, it undergoes relatively rapid drying to a self-adhesive lacquer- or paint-like coating on the medical device.
- For example, coating a stent with fibrin is well known to one of ordinary skill in the art. In U.S. Pat. No. 4,548,736 issued to Muller et al., incorporated herein by reference, fibrin is clotted by contacting fibrinogen with thrombin. Preferably, the fibrin in the fibrin-containing stent of the present invention has Factor XIII and calcium present during clotting, as described in U.S. Pat. No. 3,523,807 issued to Gerendas, incorporated herein by reference, or as described in published European Patent Application 0366564, incorporated herein by reference, in order to improve the mechanical properties and biostability of the implanted device. Preferably, the fibrinogen and thrombin used to make fibrin in the present invention are from the same animal or human species as that in which the stent will be implanted in order to avoid any inter-species immune reactions, e.g., human anti-cow. The fibrin product can be in the form of a fine, fibrin film produced by casting the combined fibrinogen and thrombin in a film and then removing moisture from the film osmotically through a semipermeable membrane. In the European Patent Application 0366564, a substrate (preferably having high porosity or high affinity for either thrombin or fibrinogen) is contacted with a fibrinogen solution and with a thrombin solution. The result is a fibrin layer formed by polymerization of fibrinogen on the surface of the medical device. Multiple layers of fibrin applied by this method could provide a fibrin layer of any desired thickness. Alternatively, the fibrin can first be clotted and then ground into a powder which is mixed with water and stamped into a desired shape in a heated mold (U.S. Pat. No. 3,523,807). Increased stability can also be achieved in the shaped fibrin by contacting the fibrin with a fixing agent such as glutaraldehyde or formaldehyde. These and other methods known by those skilled in the art for making and forming fibrin may be used in the present invention.
- If a synthetic graft is coated with collagen, the methods for preparing collagen and forming it on synthetic graft devices are well known as set forth in U,S. Patent No. 5,851,230 to Weadock et al., incorporated herein by reference. This patent describes methods for coating a synthetic graft with collagen. Methods for adhering collagen to a porous graft substrate typically include applying a collagen dispersion to the substrate, allowing it to dry and repeating the process. Collagen dispersions are typically made by blending insoluble collagen (approximately 1-2% by weight) in a dispersion at acidic pH (a pH in a range of 2 to 4). The dispersion is typically injected via syringe into the lumen of a graft and massaged manually to cover the entire inner surface area with the collagen slurry. Excess collagen slurry is removed through one of the open ends of the graft. Coating and drying steps are repeated several times to provide sufficient treatment.
- In yet another embodiment the stent or synthetic graft is coated with amorphous carbon. In U.S. Pat. No. 5,198,263, incorporated herein by reference, a method for producing a high-rate, low-temperature deposition of amorphous carbon films in the presence of a fluorinated or other halide gas is described. Deposition according to the methods of this invention can be performed at less than 100° C., including ambient room temperature, with a radio-frequency, plasma-assisted, chemical-vapor deposition process. The amorphous carbon film produced using the methods of this invention adheres well to many types of substrates, including for example glasses, metals, semiconductors, and plastics.
- Attachment of a fullerene moiety to reactive amino group sites of an amine-containing polymer to form the fullerene-graft, amine-containing polymers may be performed as described in U.S. Pat. No. 5,292,813. Chemical modification in this manner allows for direct incorporation of the fullerenes into the stent. In another embodiment, the fullerenes may be deposited on the surface of the stent or synthetic grafts as described above. (see, WO 99/32184 to Leone et al., incorporated by reference). Fullerenes may also be attached through an aldehyde bond (Yamago et al., Chemical Derivatization of Organofullerenes through Oxidation, Reduction and C-O and C-C Bond Forming Reactions. J. Org. Chem., 58 4796-4798 (1998), incorporated herein by reference). C60O may also be attached directly through an epoxide group on the fullerene to a stent. The attachment is through a covalent linkage to the oxygen. This compound and the protocols for coupling are commercially available from BuckyUSA. (BuckyUSA, Houston, Tex.).
- (E) Addition of Antibodies to the Matrix—Antibodies that promote adherence of progenitor endothelial cells can be incorporated into the matrix, either covalently or noncovalently. Antibodies may be incorporated into each layer of matrix by nixing the antibodies with the matrix coating solution. Alternatively, the antibodies may be covalently or noncovalently coated on to last layer of matrix that is applied to the medical device.
- In one embodiment, the antibodies are added to a solution containing the matrix. For example, Fab fragments on anti-CD34 monoclonal antibody are incubated with a solution containing human fibrinogen at a concentration of between 500 and 800 mg/dl. It will be appreciated that the concentration of anti-CD34 Fab fragment will vary and that one of ordinary skill in the art could determine the optimal concentration without undue experimentation. The stent is added to the Fab/fibrin mixture and the fibrin activated by addition of concentrated thrombin (at a concentration of at least 1000 U/ml). The resulting polymerized fibrin mixture containing the Fab fragments incorporated directly into the matrix is pressed into a thin film (less than 0.12 cm) on the surface of the stent or synthetic graft. Virtually any type of antibody or antibody fragment can be incorporated in this manner into a matrix solution prior to coating of a stent or synthetic graft.
- In another embodiment, antibodies are covalently coupled to the matrix. In one embodiment, the antibodies are tethered covalently to the matrix through the use of hetero- or homobifunctional linker molecules. As used herein the term “tethered” refers to a covalent coupling of the antibody to the matrix by a linker molecule. The use of linker molecules in connection with the present invention typically involves covalently coupling the linker molecules to the matrix after it is adhered to the stent. After covalent coupling to the matrix, the linker molecules provide the matrix with a number of functionally active groups that can be used to covatently couple one or more types of antibody.
FIG. 1 provides an illustration of coupling via a cross-linking molecule. An endothelial cell, 1.01, binds to an antibody, 1.03, by a cell surface antigen, 1.02. The antibody is tethered to the matrix, 1.05-1.06, by a cross-linking molecule, 1.04. The matrix, 1.05-1.06, adheres to the stent, 1.07. The linker molecules may be coupled to the matrix directly (i.e., through the carboxyl groups), or through well-known coupling chemistries, such as, esterification, amidation, and acylation. The linker molecule may be a di- or tri-amine functional compound that is coupled to the matrix through the direct formation of amide bonds, and provides amine-functional groups that are available for reaction with the antibodies. For example, the linker molecule could be a polyamine functional polymer such as polyethyleneimine (PEI), polyallylamine (PALLA) or polyethyleneglycol (PEG). A variety of PEG derivatives, e.g., mPEG-succinimidyl propionate or mPEG-N-hydroxysuccinimide, together with protocols for covalent coupling, are commercially available from Shearwater Corporation, Birmingham, Ala. (See also, Weiner et al., Influence of a poly-ethyleneglycol spacer on antigen capture by immobilized antibodies. J. Biochem. Biophys. Methods 45:211-219 (2000), incorporated herein by reference). It will be appreciated that the selection of the particular coupling agent may depend on the type of antibody used and that such selection may be made without undue experimentation. Mixtures of these polymers can also be used. These molecules contain a plurality of pendant amine-functional groups that can be used to surface-immobilize one or more antibodies. - Antibodies may be attached to C60O fullerene layers that have been deposited directly on the surface of the stent. Cross linking agents may be covalently attached to the fullerenes. The antibodies are then attached to the cross-linking agent, which in turn is attached to the stent.
FIG. 2 provides an illustration of coupling by C60O. The endothelial cell, 2.01, is bound via a cell surface antigen, 2.02, to an antibody, 2.03, which in turn is bound, covalently or non-covalently to the matrix, 2.04. The matrix, 2.04, is coupled covalently via C60O, 2.05, to the stent, 2.06. - This invention is illustrated in the experimental details section which follows. These sections set forth below the understanding of the invention, but are not intended to, and should not be construed to, limit in any way the invention as set forth in the claims which follow thereafter.
- Materials and Methods
- 1. Cells
- HUVEC will be prepared from human umbilical cords by the method of Jaffe (Jaffe, E. A. In “Biology of Endothelial Cells”, E. A. Jaffe, ed., Martinus-Nijhoff, The Hague (1984), incorporated herein by reference) and cultured in Medium 199 supplemented with 20% fetal calf serum (FCS), L-glutamine, antibiotics, 130 ug/ml heparin and 1.2 mg/ml endothelial cell growth supplement (Sigma-Aldrich, St. Louis, Mo.).
- Progenitor endothelial cells will be isolated from human peripheral blood by the method of Asahara et al. (Isolation of Putative progenitor endothelial cells for angiogenesis. Science 275:964-967). Monoclonal anti-CD34 antibodies will be coupled to magnetic beads and incubated with the leukocyte fraction of human whole blood. After incubation, bound cells will be eluted and cultured in M-199 containing 20% fetal bovine serum and bovine brain extract. (Clonetics, San Diego, Calif.). Cells will be characterized by fluorescent antibodies to CD45, CD34, CD31, Flk-1, Tie-2, and E- selectin.
- 2. Coating of Stents
- A. R stents produced by Orbus International B.V. (Leusden, The Netherlands) will be incubated with human fibrinogen (Sigma, St. Louis, Mo.) 500-800 mg/ml together with Fab fragments of anti-CD34 monoclonal antibody and the fibrinogen will be polymerized by the addition of 1000 units/ml of thrombin. After incubation of the stent with the polymerized fibrin mixture containing the anti-CD34 monoclonal Fab fragments, the fibrin will be compressed into a thin film less than 0.012 cm) against the R Stent. The R-Stent having the thin, fibrin film containing the Fab fragments will be washed three times with phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) at room temperature.
- B. Alternatively, R stents will be coated with mPEG-succinimidyl propionate (Shearwater Corporation, Birmingham, Ala.). The succinimidyl group will be reacted with the anti-CD34 monoclonal Fab fragments (Fab-PEG coated R stents) according to the manufacturer's instructions to form a stable amide linkage between the PEG derivative and the Fab fragment.
- 3. Endothelial Cell Binding Assay
- The fibrin-anti-CD34 Fab coated R-stents or Fab-PEG coated R stents will be incubated with isolated HUEC or isolated progenitor endothelial cells at cellular concentrations of between 100,000 and 1,000,000 cells/ml in M199 containing 0.5% BSA at 37° C. in a 5% CO2 humidified atmosphere. Prior to incubation with the stent, the HUVEC or progenitor endothelial cells will be labeled with [3H]-thymidine for 24 hours. After incubation of the labeled endothelial cells with the stents coated with fibrin and Fab anti-CD34 for between 4 and 72 hours, the stents will be removed from the solution and washed 5 times with M199 containing 0.5% BSA. Bound endothelial cells will be removed by trypsinization and binding of labeled endotheltal cells to the stents will be assessed by scintillation counting of [3H]-thynidine. As negative control, stents coated with fibrin alone or uncoated stents will be incubated with [3H]-thymidine-labeled endothelial cells. Results will be evaluated statistically using a t-test to determine differential binding. Stents coated with fibrin which incorporate monoclonal anti-CD34 Fab fragments will show significantly increased binding of endothelial cells as compared with uncoated stents.
- Endothelial Cell Proliferation Assay
- R stents coated with fibrin that incorporates anti-CD34 Fab fragments will be incubated with HUVEC or progenitor endothelial cells for between 4 and 72 hours in M199 containing 0.5% BSA. After incubation of the stents with the HUVEC or progenitor endothelial cells, the stents will be washed 5 times with M199 containing 0.5% BSA and then incubated with [3H]-thymidine. [3H]-thymidine incorporation will be assessed in washed and harvested HUVEC or progenitor endothelial cells (cells will be harvested with trypsin). Proliferation of HUVEC or progenitor endothelial cells on fibrin-coated stents will be compared with endothelial cell proliferation in standard microtiter dishes. Proliferation of HUVEC or progenitor endothelial cells on fibrin-coated stents will be equal to or greater than proliferation of endothelial cells in microtiter dishes
- BALB/c mice will be immunized, intraperitoneally 3-4 times at 2-4 weekly intervals, with 1.5×106 HUVEC in PBS or 1.5×105 progenitor endothelial cells and challenged 3 days prior to spleen-cell removal with 1.5×106 HUVEC or 1.5×106 progenitor endothelial cells. A spleen-cell suspension will be prepared, fused with the myeloma NS1/1 AG4.1 and hybridomas grown up and cloned. To improve hybridoma growth and cloning efficiencies, 10% endothelial-cell conditioned medium (HVEC) will be included in culture media. Initially, hybridoma culture supernatants will be tested for reactivity with HUVEC or progenitor endothelial cells by immunofluorescence flow cytometry (FACS). Briefly, HUVAC (1.5×104) or progenitor endothelial cells (1.5×104) will be incubated (30 min., 4° C.) with undiluted hybridoma supernatant, washed and incubated with fluorescein-isothiocyanate (FITC)-sheep F(ab′)2 anti-mouse Ig(100 ug/mi). Following final washing, the endothelial cells will be examined for monoclonal antibody binding by FACS analysis. Positive hybridoma supernatants will be screened on the human melanoma cell line MM-170 to eliminate non-endothelial specific mAbs. Endothelial specificity will be further confirmed by screening of monoclonal antibodies on a panel of human tumor cell lines as well as human lymphocytes, monocytes, neutrophils, red cells and platelets.
- Implantation of antibody-covered stents will be performed in juvenile Yorkshire pigs weighing between 25 and 30 kg. Animal care will comply with the “Guide for the Care and Use of Laboratory Animals” (NIH publication No. 80-23, revised 1985). After an overnight fast, animals will be sedated with ketamine hydrochloride (20 mg/kg). Following the induction of anesthesia with thiopental (12 mg/kg) the animals will be intubated and connected to a ventilator that will administer a mixture of oxygen and nitrous oxide (1:2 [vol/vol]). Anesthesia will be maintained with 0.5-2.5 vol % isoflurane, Antibiotic prophylaxis will be provided by an intramuscular injection of 1,000 mg of a mixture of procaine penicillin-G and benzathine penicillin-G (streptomycin).
- Under sterile conditions, an arteriotomy of the left carotid artery will be performed and a 9F-introducer sheath will be placed in the left carotid artery. All animals will be given 7,500 IU of heparin sodium and 100 mg of acetylsalicylic acid intravenously. Additional 2,500 IU boluses of heparin will be administered periodically throughout the procedure in order to maintain an activated clotting time above 300 seconds. An 8F guiding catheter will be introduced through the carotid sheath and passed to the origin of the iliac artery. Angiography will be performed after the administration of 1 mg of isosorbide dinitrate and images will be analyzed using a quantitative coronary angiography system. A 3F-embolectomy catheter will be inserted into the common femoral artery, and passed distal to the segment selected for stent implantation. The embolectomy balloon will be inflated to a size 0.5 mm larger than the arterial segment and withdrawn twice to denude the vessel. Immediately after denudation, a fibrin-coated stent incorporating an Fab fragment of a monoclonal antibody will be inserted through the guiding catheter and deployed in the denuded segment of the femoral artery. Animals will be sacrificed both at 3 days and at eight weeks after stent implantation. The animal will first be sedated and anesthetized as described above. The stented femoral segments will be explanted and then placed in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.2 at 4° C. for 48 h. A rectangular section of the vessel wall will be removed for further processing for electron microscopic evaluation of surface coverage of endothelial cells. This portion of the stented vessel will be placed in 0.15 cacodylate buffer and further fixed with 2.5% glutaraldehyde in 0.15 M cacodylate. The tissue will then be post-fixed with 0.1 M cacodylate buffer containing 1% OsO4 and 50 mM ferricyanide (K3[Fe(CN)6]), and further processed. (Reduction in thrombotic events with heparin-coated Palmaz-Schatz stents in normal porcine coronary arteries, Circulation 93:423-430, incorporated herein by reference).
- The remaining sections of the stented arterial segments will be impregnated with three changes of methy methacrylate as described by van Beusekom et al. (Cardiovasc Pathol 5:69-76 (1996) incorporated herein by reference). Embedded arterial segments with the stent in place will be cut into sections 3 to 5 μm thick on a motor-driven rotary microtome (H-350, Microm GmbH, Munich, Germany) using stainless steel disposable knives. On chrome aluminum coated slides, sections will be stretched on a hot plate at 40° C. using a mixture of 60% 2-butoxyethanol and 10% ethanol in water. Sections will be covered by a plastic film, excess butoxyethanol-ethanol mixture removed and the slides will be left overnight to dry in a 40° C. oven. Sections will then be deplasticized in a solution of equal volumes of xylene-chloroform for 30 to 60 minutes. Standard staining procedures for light microscopy will then be performed on the prepared sections. Statistics: Data will be presented as the mean±standard error of the mean (SD) of the independent experiments. Statistical significance will be determined by one way analysis of variance (ANOVA) and Fisher's PLSD test (StatView 4.01; Brain Power, Inc., Calabasas, Calif.) For data of treated and untreated segments of femoral arteries, a paired t test (StatView 4.01) will be used. A p value of <0.05 will be considered a statistically significant difference between the means. Animals treated with a stent incorporating an anti-porcine endothelial cell monoclonal Fab fragment will show increased endothelial cell coverage and significantly reduced restenosis as compared with controls having an uncoated stent implanted.
- Porcine progenitor endothelial cells will be isolated from pig peripheral blood by the method of Asahara et al. (Isolation of Putative progenitor endothelial cells for angiogenesis. Science 275:964-967). Monoclonal anti-CD34 antibodies will be coupled to magnetic beads and incubated with the leukocyte fraction of pig whole blood. After incubation, bound cells will be eluted and cultured in M-199 containing 20% fetal bovine serum and bovine brain extract. (Clonetics, San Diego, Calif.). Cells will be characterized by fluorescent antibodies to CD45, CD34, CD31, Flk-1, Tie-2, and E- selectin.
- For example, purified porcine progenitor endothelial cells will be transfected with vascular endothelial growth factor (VEGF) using an adenovirus vector expressing the VEGF cDNA according to the methods of Rosenaart et al. (Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann. Surg. 230(4):466-470 (1999), incorporated herein by reference).
- The transfected purified porcine progenitor cells expressing VEGF will be infused into the porcine femoral artery model after balloon injury and stent implantation as described in Example 4 using a double-balloon chamber infusion catheter (Cordis Corp) which isolates the stented portion of the femoral artery. Restenosis will be compared in balloon angioplasty stent-treated pigs infused with VEGF-transfected porcine progenitor cells as compared with pigs infused with un-transfected porcine progenitor endothelial cells. Expression of VEGF in the re-infused porcine progenitor endothelial cells will result in a decreased incidence and severity of restenosis in the anti-CD34 coated stents.
- Stent Preparation—stents will be made from 316 L stainless steel and will be cleaned and passivated by first washing in an anionic detergent in an ultrasonic cleaner and then soaked in hot nitric acid with agitation, followed by a final deionized water rinse.
- Derivatized stents will be prepared as follows—stents will be dipped into a 2% mixture of N-(2-aminoethyl-3-aminopropyl) trimethoxysilane in 95% ethanol for three minutes, removed, air dried at room temperature and then cured for 10 minutes at 110° C.
- Polyethylene glycol (PEG) Spacer Coupling—Derivatized stents will be placed in 100ml of 0.1 M MES buffer containing 10 mM Dicarboxymethyl-PEG and 500 mg of EDC added and incubated at 25° C. with constant stirring for two hours.
- Tethered Antibody—Antibodies to endothelial cells will be immobilized to the PEG functionalized stents in a one-step carbodiimide coupling reaction by immersing the stents into 150 ml of 0.1 M MES buffer (pH 4.5) into which 1.0 mg of murine anti-CD34 IgG1 antibody is dissolved and incubated at 25° C. for two hours. Stents will be removed from the solution and rinsed five times with 50 ml of phosphate buffered saline (pH 7.2) with 0.02% Tween 20.
- Reagents include: N-(2-aminoethyl-3-aminopropyl)trimethoxysilane (Degussa-Huls); MES buffer—morpholine ethane sulfonic acid buffer (Sigma, St. Louis, Mo.); EDC—1-ethyl-3-(3-dimethylaminopropyl) carbodiinde (Sigma, St. Louis, Mo.); Dicarboxymethyl-PEG -Dicarboxymethyl-poly(ethylene glycol) [MW 3400] (Shearwater, Huntsville, Ala).
- Having described several different embodiments of the invention, it is not intended that the invention is limited to these embodiments it is intended that modifications and variations may be made by one skilled in the art without departing from the spirit and scope of the invention as defined in the claims.
Claims (16)
1-51. (canceled)
52. A method for forming an endothelial cell layer in vivo, comprising administering to a patient at a site in need thereof a ligand for stem cells or progenitor cells, wherein circulating stem cells or progenitor cells are captured by the ligand.
53. The method of claim 52 , wherein the ligand is immobilized to a matrix material at the site of implantation.
54. The method of claim 52 , wherein the ligand is incorporated into a matrix material or at the site of implantation.
55. The method of claim 52 , wherein the ligand is released from genetically engineered cells at the site of implantantion.
56. The method of claim 52 , wherein the ligand specifically binds to stem cells or progenitor cells.
57. The method of claim 52 , further comprising providing molecules inducing proliferation or differentiation of stem cells or progenitor cells.
58. The method of claim 52 , wherein the matrix is formed of a natural or synthetic polymer.
59. The method of claim 53 , wherein the matrix is a fibrous mesh.
60. The method of claim 53 , wherein the ligands are tethered to the matrix.
61. The method of claim 52 , wherein the ligand is an antibody, antibody fragment or combination thereof.
62. The method of claim 61 , wherein the antibody, antibody fragment or combination thereof is selected from the group consisting of antibodies against CD45, CD34, CD31, Flk-1, Tie-2, and E-selectin.
63. The method of claim 60 , wherein the ligand and the matrix are part of a coating on a medical device.
64. The method of claim 63 , wherein the medical device comprises a stent or synthetic graft.
65. The method of claim 52 , wherein the circulating stem or progenitor cells are endothelial cells transfected with a mammalian expression vector.
66. The method of claim 65 , wherein the expression vector comprises one or more cloned genes encoding a protein selected from the group consisting of platelet derived growth factor (PDGF), fibroblast growth factor (FGF), and nitric oxide synthase.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/562,931 US20070156232A1 (en) | 2000-03-15 | 2006-11-22 | Medical Device with Coating that Promotes Endothelial Cell Adherence |
US13/589,907 US9072723B2 (en) | 2000-03-15 | 2012-08-20 | Medical device with coating that promotes endothelial cell adherence |
US14/732,489 US9555166B2 (en) | 2000-03-15 | 2015-06-05 | Medical device with coating that promotes endothelial cell adherence |
US14/831,956 US20150352263A1 (en) | 2000-03-15 | 2015-08-21 | Medical device with coating that promotes endothelial cell adherence |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18967400P | 2000-03-15 | 2000-03-15 | |
US20178900P | 2000-05-04 | 2000-05-04 | |
US09/808,867 US7037332B2 (en) | 2000-03-15 | 2001-03-15 | Medical device with coating that promotes endothelial cell adherence |
US10/832,106 US7803183B2 (en) | 2000-03-15 | 2004-04-26 | Medical device with coating that promotes endothelial cell adherence |
US11/562,931 US20070156232A1 (en) | 2000-03-15 | 2006-11-22 | Medical Device with Coating that Promotes Endothelial Cell Adherence |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/832,106 Continuation US7803183B2 (en) | 2000-03-15 | 2004-04-26 | Medical device with coating that promotes endothelial cell adherence |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/589,907 Continuation US9072723B2 (en) | 2000-03-15 | 2012-08-20 | Medical device with coating that promotes endothelial cell adherence |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070156232A1 true US20070156232A1 (en) | 2007-07-05 |
Family
ID=26885401
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/808,867 Expired - Lifetime US7037332B2 (en) | 2000-03-15 | 2001-03-15 | Medical device with coating that promotes endothelial cell adherence |
US10/832,106 Expired - Fee Related US7803183B2 (en) | 2000-03-15 | 2004-04-26 | Medical device with coating that promotes endothelial cell adherence |
US11/562,931 Abandoned US20070156232A1 (en) | 2000-03-15 | 2006-11-22 | Medical Device with Coating that Promotes Endothelial Cell Adherence |
US13/589,907 Expired - Fee Related US9072723B2 (en) | 2000-03-15 | 2012-08-20 | Medical device with coating that promotes endothelial cell adherence |
US14/732,489 Expired - Lifetime US9555166B2 (en) | 2000-03-15 | 2015-06-05 | Medical device with coating that promotes endothelial cell adherence |
US14/831,956 Abandoned US20150352263A1 (en) | 2000-03-15 | 2015-08-21 | Medical device with coating that promotes endothelial cell adherence |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/808,867 Expired - Lifetime US7037332B2 (en) | 2000-03-15 | 2001-03-15 | Medical device with coating that promotes endothelial cell adherence |
US10/832,106 Expired - Fee Related US7803183B2 (en) | 2000-03-15 | 2004-04-26 | Medical device with coating that promotes endothelial cell adherence |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/589,907 Expired - Fee Related US9072723B2 (en) | 2000-03-15 | 2012-08-20 | Medical device with coating that promotes endothelial cell adherence |
US14/732,489 Expired - Lifetime US9555166B2 (en) | 2000-03-15 | 2015-06-05 | Medical device with coating that promotes endothelial cell adherence |
US14/831,956 Abandoned US20150352263A1 (en) | 2000-03-15 | 2015-08-21 | Medical device with coating that promotes endothelial cell adherence |
Country Status (12)
Country | Link |
---|---|
US (6) | US7037332B2 (en) |
EP (1) | EP1263484B1 (en) |
JP (3) | JP5859179B2 (en) |
KR (1) | KR100860860B1 (en) |
CN (1) | CN100506293C (en) |
AT (1) | ATE362382T1 (en) |
AU (1) | AU2001245734A1 (en) |
CA (1) | CA2400319C (en) |
DE (1) | DE60128451T2 (en) |
ES (1) | ES2283398T3 (en) |
IL (1) | IL151501A0 (en) |
WO (1) | WO2001068158A1 (en) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030229393A1 (en) * | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
US20050238689A1 (en) * | 2004-04-05 | 2005-10-27 | Medivas, Llc | Bioactive stents for type II diabetics and methods for use thereof |
US20100040664A1 (en) * | 2008-08-13 | 2010-02-18 | Medivas, Llc | Aabb-poly(depsipeptide) biodegradable polymers and methods of use |
US20100228335A1 (en) * | 2009-03-04 | 2010-09-09 | John Schorgl | Stents modified with material comprising amnion tissue and corresponding processes |
US20110125251A1 (en) * | 2009-05-14 | 2011-05-26 | Orbusneich Medical, Inc. | Self-Expanding Stent with Polygon Transition Zone |
US20110137406A1 (en) * | 2004-04-05 | 2011-06-09 | Medivas, Llc | Bioactive stents for type ii diabetics and methods for use thereof |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
WO2012121507A2 (en) * | 2011-03-10 | 2012-09-13 | 서울대학교 산학협력단 | Stent able to selectively capture vascular endothelial progenitor cells and a production method therefor |
US8652504B2 (en) | 2005-09-22 | 2014-02-18 | Medivas, Llc | Solid polymer delivery compositions and methods for use thereof |
US9102830B2 (en) | 2005-09-22 | 2015-08-11 | Medivas, Llc | Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use |
US9517203B2 (en) | 2000-08-30 | 2016-12-13 | Mediv As, Llc | Polymer particle delivery compositions and methods of use |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US20170340463A1 (en) * | 2014-11-11 | 2017-11-30 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Super elastic, bioabsorbable endovascular devices |
US9873764B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Particles comprising polyesteramide copolymers for drug delivery |
US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
US10434071B2 (en) | 2014-12-18 | 2019-10-08 | Dsm Ip Assets, B.V. | Drug delivery system for delivery of acid sensitivity drugs |
Families Citing this family (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU716005B2 (en) | 1995-06-07 | 2000-02-17 | Cook Medical Technologies Llc | Implantable medical device |
US6638237B1 (en) * | 1999-08-04 | 2003-10-28 | Percardia, Inc. | Left ventricular conduits and methods for delivery |
US7220276B1 (en) * | 2000-03-06 | 2007-05-22 | Surmodics, Inc. | Endovascular graft coatings |
US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
ES2283398T3 (en) | 2000-03-15 | 2007-11-01 | Orbusneich Medical, Inc. | COATING THAT IMPROVES THE ADHERENCE OF ENDOTHELIAL CELLS. |
US20070055367A1 (en) * | 2000-03-15 | 2007-03-08 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence and differentiation |
US9320829B2 (en) * | 2000-03-15 | 2016-04-26 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20050271701A1 (en) * | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8460367B2 (en) * | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US6854467B2 (en) * | 2000-05-04 | 2005-02-15 | Percardia, Inc. | Methods and devices for delivering a ventricular stent |
US8632583B2 (en) | 2011-05-09 | 2014-01-21 | Palmaz Scientific, Inc. | Implantable medical device having enhanced endothelial migration features and methods of making the same |
US20020032478A1 (en) * | 2000-08-07 | 2002-03-14 | Percardia, Inc. | Myocardial stents and related methods of providing direct blood flow from a heart chamber to a coronary vessel |
US8192484B2 (en) | 2000-12-12 | 2012-06-05 | Cardiatis S.A. | Stent for blood flow improvement |
US6976990B2 (en) * | 2001-01-25 | 2005-12-20 | Percardia, Inc. | Intravascular ventriculocoronary bypass via a septal passageway |
DE10122806A1 (en) * | 2001-05-10 | 2002-11-14 | Holger Kiesewetter | Method for the detection of blood cell antigens and antibodies directed against them |
US7666462B2 (en) * | 2001-05-11 | 2010-02-23 | Exogenesis Corporation | Method of controlling a drug release rate |
US8889169B2 (en) * | 2001-05-11 | 2014-11-18 | Exogenesis Corporation | Drug delivery system and method of manufacturing thereof |
US7923055B2 (en) | 2001-05-11 | 2011-04-12 | Exogenesis Corporation | Method of manufacturing a drug delivery system |
US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
US7572288B2 (en) * | 2001-07-20 | 2009-08-11 | Microvention, Inc. | Aneurysm treatment device and method of use |
US8715312B2 (en) | 2001-07-20 | 2014-05-06 | Microvention, Inc. | Aneurysm treatment device and method of use |
US8252040B2 (en) | 2001-07-20 | 2012-08-28 | Microvention, Inc. | Aneurysm treatment device and method of use |
US20030036698A1 (en) * | 2001-08-16 | 2003-02-20 | Robert Kohler | Interventional diagnostic catheter and a method for using a catheter to access artificial cardiac shunts |
CA2457189C (en) * | 2001-09-28 | 2011-08-09 | Boston Scientific Limited | Medical devices comprising nanomaterials and therapeutic methods utilizing the same |
AU2002359340A1 (en) * | 2001-10-31 | 2003-05-12 | Ventrigraft Inc | Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo |
US20030109824A1 (en) * | 2001-11-07 | 2003-06-12 | Microvena Corporation | Distal protection device with local drug delivery to maintain patency |
AU2003217271A1 (en) | 2002-01-29 | 2003-09-02 | A. Mark Colb | Endothelialization of vascular surfaces |
CN100455275C (en) * | 2002-02-06 | 2009-01-28 | 祥丰医疗有限公司 | Medical device with coating that promotes endothelial cell adherence and differentiation |
US7008397B2 (en) * | 2002-02-13 | 2006-03-07 | Percardia, Inc. | Cardiac implant and methods |
US7758889B1 (en) | 2002-07-24 | 2010-07-20 | Luna Innovations Incorporated | Fullerenes in targeted therapies |
US20080193490A1 (en) * | 2002-02-14 | 2008-08-14 | Andreas Hirsch | Use of Carbon Nanotube for Drug Delivery |
US20030215454A1 (en) * | 2002-03-01 | 2003-11-20 | Colb A. Mark | Binding of red blood cells to exposed subendothelial surfaces to impede platelet deposition thereon and/or for use in targeted drug delivery thereto |
US6905667B1 (en) | 2002-05-02 | 2005-06-14 | Zyvex Corporation | Polymer and method for using the polymer for noncovalently functionalizing nanotubes |
WO2003092763A1 (en) * | 2002-05-03 | 2003-11-13 | Duke University | Carbon nanotubules for storage of nitric oxide |
EP1364663A1 (en) * | 2002-05-21 | 2003-11-26 | Commonwealth Scientific And Industrial Research Organisation | Ocular devices with functionalized surface with adhesive properties |
EP1516597A4 (en) * | 2002-06-27 | 2010-11-10 | Microport Medical Shanghai Co | Drug eluting stent |
EP1551569B1 (en) | 2002-09-26 | 2017-05-10 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable materials having engineered surfaces and method of making same |
US8679517B2 (en) | 2002-09-26 | 2014-03-25 | Palmaz Scientific, Inc. | Implantable materials having engineered surfaces made by vacuum deposition and method of making same |
US8268340B2 (en) | 2002-09-26 | 2012-09-18 | Advanced Bio Prosthetic Surfaces, Ltd. | Implantable materials having engineered surfaces and method of making same |
US7162308B2 (en) | 2002-11-26 | 2007-01-09 | Wilson Greatbatch Technologies, Inc. | Nanotube coatings for implantable electrodes |
US7060684B1 (en) | 2002-12-16 | 2006-06-13 | Quijano Rodolfo C | Device for treating diabetes and methods thereof |
US7311727B2 (en) * | 2003-02-05 | 2007-12-25 | Board Of Trustees Of The University Of Arkansas | Encased stent |
WO2004075781A2 (en) * | 2003-02-26 | 2004-09-10 | Medivas, Llc | Bioactive stents and methods for use thereof |
US20050038498A1 (en) * | 2003-04-17 | 2005-02-17 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US7074294B2 (en) * | 2003-04-17 | 2006-07-11 | Nanosys, Inc. | Structures, systems and methods for joining articles and materials and uses therefor |
US20060122596A1 (en) * | 2003-04-17 | 2006-06-08 | Nanosys, Inc. | Structures, systems and methods for joining articles and materials and uses therefor |
US7579077B2 (en) * | 2003-05-05 | 2009-08-25 | Nanosys, Inc. | Nanofiber surfaces for use in enhanced surface area applications |
US20050221072A1 (en) * | 2003-04-17 | 2005-10-06 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
US7056409B2 (en) * | 2003-04-17 | 2006-06-06 | Nanosys, Inc. | Structures, systems and methods for joining articles and materials and uses therefor |
US7972616B2 (en) | 2003-04-17 | 2011-07-05 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
JP4871726B2 (en) * | 2003-04-28 | 2012-02-08 | ナノシス・インク. | Super lyophobic surface, its preparation and use |
US7803574B2 (en) | 2003-05-05 | 2010-09-28 | Nanosys, Inc. | Medical device applications of nanostructured surfaces |
TWI427709B (en) * | 2003-05-05 | 2014-02-21 | Nanosys Inc | Nanofiber surfaces for use in enhanced surface area applications |
JP2007502708A (en) | 2003-05-16 | 2007-02-15 | ブルー メンブレーンス ゲーエムベーハー | Method for coating a substrate with a carbon-based material |
JP2004344469A (en) * | 2003-05-23 | 2004-12-09 | Terumo Corp | Medical device for embedding in living body |
US20070092489A1 (en) * | 2003-08-13 | 2007-04-26 | The Children's Hospital Of Philadelphia | Use of receptor sequences for immobilizing gene vectors on surfaces |
US20050124896A1 (en) | 2003-08-25 | 2005-06-09 | Jacob Richter | Method for protecting implantable sensors and protected implantable sensors |
US20060188486A1 (en) * | 2003-10-14 | 2006-08-24 | Medivas, Llc | Wound care polymer compositions and methods for use thereof |
US20050096509A1 (en) * | 2003-11-04 | 2005-05-05 | Greg Olson | Nanotube treatments for internal medical devices |
EP1682210A4 (en) | 2003-11-07 | 2009-11-04 | Merlin Md Pte Ltd | Implantable medical devices with enhanced visibility, mechanical properties and biocompatibility |
US20060085062A1 (en) * | 2003-11-28 | 2006-04-20 | Medlogics Device Corporation | Implantable stent with endothelialization factor |
US8465453B2 (en) * | 2003-12-03 | 2013-06-18 | Mayo Foundation For Medical Education And Research | Kits, apparatus and methods for magnetically coating medical devices with living cells |
US20090118817A1 (en) * | 2005-06-16 | 2009-05-07 | Mayo Foundation For Medical Education And Research | Magnetic Medical Apparatus, Kits, and Methods |
JP4618997B2 (en) * | 2003-12-09 | 2011-01-26 | テルモ株式会社 | Stent and manufacturing method thereof |
US20050153309A1 (en) | 2003-12-22 | 2005-07-14 | David Hoon | Method and apparatus for in vivo surveillance of circulating biological components |
US20110039690A1 (en) | 2004-02-02 | 2011-02-17 | Nanosys, Inc. | Porous substrates, articles, systems and compositions comprising nanofibers and methods of their use and production |
US8025960B2 (en) | 2004-02-02 | 2011-09-27 | Nanosys, Inc. | Porous substrates, articles, systems and compositions comprising nanofibers and methods of their use and production |
US20050175667A1 (en) * | 2004-02-10 | 2005-08-11 | Wenda Carlyle | Use of endothelin antagonists to prevent restenosis |
EP1753476B1 (en) * | 2004-03-10 | 2015-07-29 | OrbusNeich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
WO2005094725A1 (en) | 2004-03-31 | 2005-10-13 | Merlin Md Pte Ltd | A method for treating aneurysms |
US8715340B2 (en) * | 2004-03-31 | 2014-05-06 | Merlin Md Pte Ltd. | Endovascular device with membrane |
SG133420A1 (en) * | 2005-12-13 | 2007-07-30 | Merlin Md Pte Ltd | An endovascular device with membrane having permanently attached agents |
US8500751B2 (en) | 2004-03-31 | 2013-08-06 | Merlin Md Pte Ltd | Medical device |
US20050234545A1 (en) * | 2004-04-19 | 2005-10-20 | Yea-Yang Su | Amorphous oxide surface film for metallic implantable devices and method for production thereof |
EP2946666B1 (en) * | 2004-04-30 | 2017-11-15 | OrbusNeich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
US20050260355A1 (en) * | 2004-05-20 | 2005-11-24 | Jan Weber | Medical devices and methods of making the same |
EP1766405A1 (en) * | 2004-05-21 | 2007-03-28 | MDS Inc. doing Business Through Its MDS Pharma Services Division | Method of quantifying the cell-binding properties of a medical device |
CA2566904A1 (en) * | 2004-06-07 | 2005-12-22 | Conor Medsystems, Inc. | Local delivery of growth factors for stem cell transplantation |
EP1793875B9 (en) * | 2004-06-16 | 2010-09-08 | Affinergy, Inc. | Ifbm's to promote attachment of target analytes |
US20060093642A1 (en) * | 2004-11-03 | 2006-05-04 | Ranade Shrirang V | Method of incorporating carbon nanotubes in a medical appliance, a carbon nanotube medical appliance, and a medical appliance coated using carbon nanotube technology |
GB2420976B (en) * | 2004-11-19 | 2006-12-20 | Zvi Finkelstein | Therapeutic implant |
US8609123B2 (en) * | 2004-11-29 | 2013-12-17 | Advanced Cardiovascular Systems, Inc. | Derivatized poly(ester amide) as a biobeneficial coating |
ES2490610T3 (en) * | 2004-12-08 | 2014-09-04 | Shire Regenerative Medicine, Inc. | Materials and methods for minimally invasive administration of a fluid composition containing cells |
US20060136042A1 (en) * | 2004-12-22 | 2006-06-22 | Scimed Life Systems, Inc. | Vulnerable plaque stent |
CA2509083A1 (en) * | 2004-12-22 | 2006-06-22 | Merlin Md Pte Ltd | A medical device |
US8158410B2 (en) * | 2005-01-18 | 2012-04-17 | Biocept, Inc. | Recovery of rare cells using a microchannel apparatus with patterned posts |
EP1848470A2 (en) * | 2005-02-17 | 2007-10-31 | Abbott Cardiovascular Systems, Inc. | Coatings for implantable medical devices containing attractants for endothelial cells |
US20070003589A1 (en) * | 2005-02-17 | 2007-01-04 | Irina Astafieva | Coatings for implantable medical devices containing attractants for endothelial cells |
EP1868529A2 (en) * | 2005-03-09 | 2007-12-26 | The University of Tennessee Research Foundation | Barrier stent and use thereof |
CA2605080A1 (en) * | 2005-04-21 | 2006-11-02 | Massachusetts Institute Of Technology | Materials and methods for altering an immune response to exogenous and endogenous immunogens, including syngeneic and non-syngeneic cells, tissues or organs |
US8414907B2 (en) * | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
US9119901B2 (en) * | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
ES2263382B1 (en) * | 2005-05-16 | 2007-11-16 | Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon | ARTIFICIAL MATRIX OF ENDOTHELIZED FIBRINE GEL SUPERPRODUCTOR OF PROANGIOGEN FACTORS. |
EP1901680B1 (en) * | 2005-06-21 | 2015-04-15 | Shire Regenerative Medicine, Inc. | Crypreservation of biocompatible material |
KR101377900B1 (en) | 2005-10-13 | 2014-03-27 | 신세스 게엠바하 | Drug-impregnated encasement |
US20070196423A1 (en) * | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
US20100204783A1 (en) * | 2005-12-06 | 2010-08-12 | Helen Marie Nugent | Methods and compositions for enhancing vascular access |
WO2007067744A2 (en) * | 2005-12-07 | 2007-06-14 | Medivas, Llc | Method for assembling a polymer-biologic delivery composition |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US7807624B2 (en) * | 2006-01-11 | 2010-10-05 | Affinergy, Inc. | Methods and compositions for promoting attachment of cells of endothelial cell lineage to medical devices |
US7531505B2 (en) * | 2006-01-11 | 2009-05-12 | Affinergy, Inc. | Compositions and methods for promoting attachment of cells of endothelial cell lineage to medical devices |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US20100023101A1 (en) * | 2006-02-03 | 2010-01-28 | University Of Wollongong | Biocompatible composites |
US20070191766A1 (en) * | 2006-02-10 | 2007-08-16 | Boston Scientific Scimed, Inc. | Balloon catheter having nanotubes |
AU2006338324A1 (en) * | 2006-02-13 | 2007-08-23 | Merlin Md Pte Ltd | Endovascular device with membrane |
US20070203564A1 (en) * | 2006-02-28 | 2007-08-30 | Boston Scientific Scimed, Inc. | Biodegradable implants having accelerated biodegradation properties in vivo |
US20070225795A1 (en) * | 2006-03-24 | 2007-09-27 | Juan Granada | Composite vascular prosthesis |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
CA2649672C (en) * | 2006-05-02 | 2015-07-07 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
US20070282011A1 (en) * | 2006-05-09 | 2007-12-06 | Medivas, Llc | Biodegradable water soluble polymers |
US7572625B2 (en) * | 2006-05-18 | 2009-08-11 | Boston Scientific Scimed, Inc. | Medical devices coated with drug carrier macromolecules |
EP2716307B1 (en) * | 2006-06-13 | 2022-08-03 | Alchimedics | Drug eluting stent with a biodegradable release layer attached with an electro-grafted primer coating |
US20080108138A1 (en) * | 2006-06-13 | 2008-05-08 | Vermette Patrick | Bioactive compositions and their use in cell patterning |
US8535372B1 (en) * | 2006-06-16 | 2013-09-17 | Abbott Cardiovascular Systems Inc. | Bioabsorbable stent with prohealing layer |
US8066753B2 (en) | 2006-07-06 | 2011-11-29 | Robert Kipperman | Specialized catheter and method for placement in a bifurcated vessel |
US7824438B2 (en) * | 2006-07-06 | 2010-11-02 | Robert Kipperman | Method for placement of a stent assembly in a bifurcated vessel |
EP2054537A2 (en) | 2006-08-02 | 2009-05-06 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US20080085293A1 (en) * | 2006-08-22 | 2008-04-10 | Jenchen Yang | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor |
WO2008030388A2 (en) * | 2006-09-06 | 2008-03-13 | Boston Scientific Scimed, Inc. | Medical devices having a coating for promoting endothelial cell adhesion |
EP2399616A1 (en) | 2006-09-15 | 2011-12-28 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
JP2010503489A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
EP2068782B1 (en) | 2006-09-15 | 2011-07-27 | Boston Scientific Limited | Bioerodible endoprostheses |
JP2010503482A (en) | 2006-09-18 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis |
WO2008039521A2 (en) * | 2006-09-26 | 2008-04-03 | Nmt Medical, Inc. | Method for modifying a medical implant surface for promoting tissue growth |
WO2008063157A2 (en) * | 2006-10-25 | 2008-05-29 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | A nanoparticle-based anticoagulant |
SG176460A1 (en) * | 2006-11-07 | 2011-12-29 | Pervasis Therapeutics Inc | Materials and methods for treating and managing angiogenesis-mediated diseases |
EP2277563B1 (en) | 2006-12-28 | 2014-06-25 | Boston Scientific Limited | Bioerodible endoprostheses and method of making the same |
EP2111185B1 (en) | 2007-01-30 | 2017-12-20 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Bioerodible wraps and uses therefor |
US20080311172A1 (en) * | 2007-04-25 | 2008-12-18 | Schapira Jay N | Programmed-release, nanostructured biological construct |
EP2167180B1 (en) * | 2007-06-01 | 2015-03-04 | Covidien LP | Extension tubes for balloon catheters |
US20100070020A1 (en) | 2008-06-11 | 2010-03-18 | Nanovasc, Inc. | Implantable Medical Device |
EP2155294B1 (en) * | 2007-06-13 | 2012-02-15 | Pervasis Therapeutics, Inc. | Methods and devices for minimally-invasive delivery of cell-containing flowable compositions |
CN105943208B (en) | 2007-06-25 | 2019-02-15 | 微仙美国有限公司 | Self-expanding prosthesis |
EP2178944A1 (en) * | 2007-07-24 | 2010-04-28 | Medivas, LLC | Biodegradable cationic polymer gene transfer compositions and methods of use |
US20090043380A1 (en) * | 2007-08-09 | 2009-02-12 | Specialized Vascular Technologies, Inc. | Coatings for promoting endothelization of medical devices |
US20090043330A1 (en) * | 2007-08-09 | 2009-02-12 | Specialized Vascular Technologies, Inc. | Embolic protection devices and methods |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
WO2009041691A1 (en) | 2007-09-28 | 2009-04-02 | Terumo Kabushiki Kaisha | In-vivo indwelling matter |
CN101172168B (en) * | 2007-10-10 | 2010-06-02 | 大连理工大学 | Metallic blood vessel bracket coating for osamine glycan load CD133 antibody and method for preparing the same |
US20090112239A1 (en) * | 2007-10-31 | 2009-04-30 | Specialized Vascular Technologies, Inc. | Sticky dilatation balloon and methods of using |
US8319002B2 (en) | 2007-12-06 | 2012-11-27 | Nanosys, Inc. | Nanostructure-enhanced platelet binding and hemostatic structures |
CN101883545B (en) | 2007-12-06 | 2013-08-07 | 纳诺西斯有限公司 | Resorbable nanoenhanced hemostatic structures and bandage materials |
JP2011509157A (en) * | 2008-01-09 | 2011-03-24 | イノベイテイブ ヘルス テクノロジーズ エルエルシー | Implant pellets and methods for bone formation and preservation |
JP5435878B2 (en) * | 2008-02-12 | 2014-03-05 | 富士フイルム株式会社 | Labeled particles with fragmented antibody immobilized on labeling substance |
WO2009114089A2 (en) * | 2008-03-03 | 2009-09-17 | Luna Innovations Incorporated | Using fullerenes to enhance and stimulate hair growth |
US20110190251A1 (en) * | 2008-03-03 | 2011-08-04 | Kepley Christopher L | Method for inhibiting the build-up of arterial plaque by administering fullerenes |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US20100022940A1 (en) * | 2008-07-25 | 2010-01-28 | Medtronic Vascular, Inc. | Percutaneously Introduceable Shunt Devices and Methods |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
EP2323708A4 (en) * | 2008-08-07 | 2015-11-18 | Exogenesis Corp | Drug delivery system and method of munufacturing thereof |
WO2010017451A2 (en) * | 2008-08-07 | 2010-02-11 | Exogenesis Corporation | Medical device for bone implant and method for producing such a device |
US8642063B2 (en) | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
US8262692B2 (en) * | 2008-09-05 | 2012-09-11 | Merlin Md Pte Ltd | Endovascular device |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US20100119578A1 (en) * | 2008-11-07 | 2010-05-13 | Specialized Vascular Technologies, Inc. | Extracellular matrix modulating coatings for medical devices |
US8540889B1 (en) | 2008-11-19 | 2013-09-24 | Nanosys, Inc. | Methods of generating liquidphobic surfaces |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US8574612B2 (en) * | 2009-03-04 | 2013-11-05 | Boston Scientific Scimed, Inc. | Medical devices having a coating of biologic macromolecules |
US8382818B2 (en) | 2009-07-02 | 2013-02-26 | Tryton Medical, Inc. | Ostium support for treating vascular bifurcations |
JP5782029B2 (en) * | 2009-08-12 | 2015-09-24 | デューク ユニバーシティーDuke University | Implantable device coated with cells |
US9446051B2 (en) * | 2009-10-19 | 2016-09-20 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
AU2010308308B2 (en) | 2009-10-19 | 2013-11-28 | The Population Council, Inc. | Neuroprotection and myelin repair using nestorone® |
EP2493418B1 (en) | 2009-10-28 | 2017-03-15 | University of Pittsburgh - Of the Commonwealth System of Higher Education | Bioerodible wraps and uses therefor |
CA2784021C (en) * | 2009-12-16 | 2018-03-20 | Neograft Technologies, Inc. | Graft devices and methods of use |
WO2011082227A1 (en) | 2009-12-29 | 2011-07-07 | Boston Scientific Scimed, Inc. | High strength low opening pressure stent design |
US9295541B2 (en) | 2009-12-31 | 2016-03-29 | Neograft Technologies, Inc. | Graft devices and methods of fabrication |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US8579964B2 (en) | 2010-05-05 | 2013-11-12 | Neovasc Inc. | Transcatheter mitral valve prosthesis |
EP2595695B1 (en) | 2010-07-19 | 2019-02-06 | Neograft Technologies, Inc. | Graft devices and methods of use |
US9861814B2 (en) * | 2010-12-23 | 2018-01-09 | Medtronic, Inc. | Medical electrical lead having biological surface and methods of making and using same |
US9554897B2 (en) | 2011-04-28 | 2017-01-31 | Neovasc Tiara Inc. | Methods and apparatus for engaging a valve prosthesis with tissue |
US9308087B2 (en) | 2011-04-28 | 2016-04-12 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US8728563B2 (en) | 2011-05-03 | 2014-05-20 | Palmaz Scientific, Inc. | Endoluminal implantable surfaces, stents, and grafts and method of making same |
CA2835427A1 (en) | 2011-05-11 | 2012-11-15 | Microvention, Inc. | Device for occluding a lumen |
US9579224B2 (en) | 2011-07-25 | 2017-02-28 | Neograft Technologies, Inc. | Vessel remodeling methods and devices for use in a graft device |
GB201114293D0 (en) | 2011-08-19 | 2011-10-05 | Univ Edinburgh | Endothelial polymers |
US9381112B1 (en) | 2011-10-06 | 2016-07-05 | William Eric Sponsell | Bleb drainage device, ophthalmological product and methods |
ITVI20110310A1 (en) * | 2011-11-29 | 2013-05-30 | Ehsan Bahrami | COMBINATORIAL COATING INCLUDING TWO CHEMICAL PROTEINS TO INCREASE THE ATTRACTION OF ENDOTELIAL CELLS AND ENDOTHIAL PROGENITRIC CELLS ON A METALLIC SURFACE |
US8632489B1 (en) | 2011-12-22 | 2014-01-21 | A. Mateen Ahmed | Implantable medical assembly and methods |
TWI590843B (en) | 2011-12-28 | 2017-07-11 | 信迪思有限公司 | Films and methods of manufacture |
EP2833837B1 (en) | 2012-04-06 | 2023-03-29 | Merlin MD PTE Ltd. | Devices for treating an aneurysm |
EP2841024B1 (en) | 2012-04-26 | 2017-05-03 | Tryton Medical, Inc. | Support for treating vascular bifurcations |
US9345573B2 (en) | 2012-05-30 | 2016-05-24 | Neovasc Tiara Inc. | Methods and apparatus for loading a prosthesis onto a delivery system |
US9572665B2 (en) | 2013-04-04 | 2017-02-21 | Neovasc Tiara Inc. | Methods and apparatus for delivering a prosthetic valve to a beating heart |
KR102249720B1 (en) | 2013-06-21 | 2021-05-11 | 디퍼이 신테스 프로덕츠, 인코포레이티드 | Films and methods of manufacture |
EP3157408A4 (en) | 2014-06-17 | 2018-03-07 | Ganiban, Gary | Devices and methods to provide hands free scleral depression during ophthalmic procedures |
CN104383609B (en) * | 2014-11-07 | 2016-09-14 | 浙江大学 | The application in screening endotheliocyte and smooth muscle cell of the material of a kind of controllable cell adhesion |
CN108367097A (en) | 2015-12-19 | 2018-08-03 | 心脏起搏器股份公司 | Biologically inert coating for implantable medical device |
CN108882981B (en) | 2016-01-29 | 2021-08-10 | 内奥瓦斯克迪亚拉公司 | Prosthetic valve for preventing outflow obstruction |
CN109561890A (en) | 2016-06-09 | 2019-04-02 | 海马切克公司 | For detecting the collector with the cell reversibly captured in vivo body fluid |
WO2017218787A1 (en) | 2016-06-16 | 2017-12-21 | Cardiac Pacemakers, Inc. | Hydrophilization and antifouling of enhanced metal surfaces |
EP3496771B1 (en) | 2016-08-09 | 2023-01-04 | Cardiac Pacemakers, Inc. | Functionalized peg for implantable medical devices |
US20180206851A1 (en) * | 2016-10-19 | 2018-07-26 | Daniel E. Walzman | Hydrogel intrasaccular occlusion device |
CN109996581B (en) | 2016-11-21 | 2021-10-15 | 内奥瓦斯克迪亚拉公司 | Methods and systems for rapid retrieval of transcatheter heart valve delivery systems |
US10603485B2 (en) | 2016-11-28 | 2020-03-31 | Boston Scientific Neuromodulation Corporation | Features in increased surface area on neuromodulation leads |
CN108619581A (en) * | 2017-03-21 | 2018-10-09 | 微创心脉医疗科技(上海)有限公司 | The application of medication coat, interventional medical device and epiphysin in medication coat |
US11129926B2 (en) | 2017-04-13 | 2021-09-28 | Orbusneich Medical Pte. Ltd. | Medical devices coated with polydopamine and antibodies |
US10433852B2 (en) | 2017-05-08 | 2019-10-08 | William Z. H'Doubler | Aortic occlusion balloon apparatus, system and method of making |
CA3073834A1 (en) | 2017-08-25 | 2019-02-28 | Neovasc Tiara Inc. | Sequentially deployed transcatheter mitral valve prosthesis |
US11864728B2 (en) * | 2017-12-28 | 2024-01-09 | Cilag Gmbh International | Characterization of tissue irregularities through the use of mono-chromatic light refractivity |
DE102018110591B4 (en) * | 2018-05-03 | 2022-11-03 | Acandis Gmbh | Medical device with a fibrin coating, system and set with such a device and method of manufacture |
JP2021534906A (en) * | 2018-08-31 | 2021-12-16 | ウィスコンシン アラムニ リサーチ ファンデーション | Generation of vascular grafts seeded with arterial endothelial cells |
AU2019374743B2 (en) | 2018-11-08 | 2022-03-03 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
US11998447B2 (en) | 2019-03-08 | 2024-06-04 | Neovasc Tiara Inc. | Retrievable prosthesis delivery system |
CA3135753C (en) | 2019-04-01 | 2023-10-24 | Neovasc Tiara Inc. | Controllably deployable prosthetic valve |
CA3136334A1 (en) | 2019-04-10 | 2020-10-15 | Neovasc Tiara Inc. | Prosthetic valve with natural blood flow |
EP3972673A4 (en) | 2019-05-20 | 2023-06-07 | Neovasc Tiara Inc. | Introducer with hemostasis mechanism |
CA3143344A1 (en) | 2019-06-20 | 2020-12-24 | Neovasc Tiara Inc. | Low profile prosthetic mitral valve |
CN110917410B (en) * | 2019-11-14 | 2020-11-24 | 浙江大学 | Cardiovascular stent coating based on double-layer heterogeneous structure and preparation method thereof |
CN115052639A (en) * | 2020-02-06 | 2022-09-13 | 信越化学工业株式会社 | Angiogenesis device |
CN113713172B (en) * | 2021-09-08 | 2023-04-11 | 深圳清华大学研究院 | In-situ endothelialization promoting coating and preparation method thereof |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
US6171609B1 (en) * | 1995-02-15 | 2001-01-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6342390B1 (en) * | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
US6375680B1 (en) * | 1998-12-01 | 2002-04-23 | St. Jude Medical, Inc. | Substrates for forming synthetic tissues |
US6464889B1 (en) * | 1996-01-22 | 2002-10-15 | Etex Corporation | Surface modification of medical implants |
US6503273B1 (en) * | 1999-11-22 | 2003-01-07 | Cyograft Tissue Engineering, Inc. | Tissue engineered blood vessels and methods and apparatus for their manufacture |
US6583276B1 (en) * | 1996-09-06 | 2003-06-24 | Technion Research And Development Co., Ltd. | Angiogenic factors and use thereof in treating cardiovascular disease |
US6607724B2 (en) * | 1998-10-08 | 2003-08-19 | Children's Hospital | Compositions and methods for inhibiting angiogenesis |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
US6673341B2 (en) * | 1998-07-06 | 2004-01-06 | Beth Israel Deaconness Medical Center | Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis |
US6790606B1 (en) * | 1996-03-15 | 2004-09-14 | Munin Corporation | Extracellular matrix signaling molecules |
US7037332B2 (en) * | 2000-03-15 | 2006-05-02 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence |
Family Cites Families (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3523807A (en) | 1966-11-25 | 1970-08-11 | Mihaly Gerendas | Method of making a cross-linked fibrin prosthesis |
JPS5313915B2 (en) | 1973-01-25 | 1978-05-13 | ||
US4515160A (en) | 1982-04-23 | 1985-05-07 | Medtronic, Inc. | Cardiac pacemaker synchronized programming |
US4487715A (en) | 1982-07-09 | 1984-12-11 | The Regents Of The University Of California | Method of conjugating oligopeptides |
US4548736A (en) | 1983-08-29 | 1985-10-22 | Wisconsin Alumni Research Foundation | Preparation of protein films |
US4553974A (en) | 1984-08-14 | 1985-11-19 | Mayo Foundation | Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor |
US4889808A (en) * | 1985-10-01 | 1989-12-26 | American Home Products | Method of enchancing t-PA and SCU-PA production |
JPS62235568A (en) * | 1985-12-05 | 1987-10-15 | ドクタ− ミユ−ラ−−リ−ルハイム ケ−ジ− バイオロジツシエ ラボラトリ−ン | Carrier biochemically activated by antibody covalent-bonded with surface |
US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
US4920016A (en) | 1986-12-24 | 1990-04-24 | Linear Technology, Inc. | Liposomes with enhanced circulation time |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US4795459A (en) | 1987-05-18 | 1989-01-03 | Rhode Island Hospital | Implantable prosthetic device with lectin linked endothelial cells |
US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
EP0366564B1 (en) | 1988-10-28 | 1995-07-12 | Terumo Kabushiki Kaisha | Antithrombic medical material, artificial internal organ, and method for production of antithrombic medical material |
US5043165A (en) | 1988-12-14 | 1991-08-27 | Liposome Technology, Inc. | Novel liposome composition for sustained release of steroidal drugs |
US5011778A (en) * | 1989-05-23 | 1991-04-30 | Otsuka Pharmaceutical Co., Ltd. | Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies |
US5635386A (en) | 1989-06-15 | 1997-06-03 | The Regents Of The University Of Michigan | Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture |
JPH0366384A (en) | 1989-08-04 | 1991-03-22 | Senjiyu Seiyaku Kk | System for controlling release of physiologically active material |
US5674848A (en) | 1989-08-14 | 1997-10-07 | The Regents Of The University Of California | Bioreactor compositions with enhanced cell binding |
US5635482A (en) | 1989-08-14 | 1997-06-03 | The Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
US5059166A (en) | 1989-12-11 | 1991-10-22 | Medical Innovative Technologies R & D Limited Partnership | Intra-arterial stent with the capability to inhibit intimal hyperplasia |
US5674192A (en) * | 1990-12-28 | 1997-10-07 | Boston Scientific Corporation | Drug delivery |
US5199939B1 (en) | 1990-02-23 | 1998-08-18 | Michael D Dake | Radioactive catheter |
EP0470246B1 (en) | 1990-02-28 | 1995-06-28 | Medtronic, Inc. | Intralumenal drug eluting prosthesis |
US7196054B1 (en) * | 1990-11-27 | 2007-03-27 | The American National Red Cross | Methods for treating wound tissue and forming a supplemented fibrin matrix |
US5492890A (en) * | 1990-12-03 | 1996-02-20 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
DE4202282A1 (en) * | 1991-01-29 | 1992-08-20 | Fuji Photo Film Co Ltd | LIGHT SENSITIVE TRANSMISSION MATERIAL AND PICTURE PRODUCTION METHOD |
US5198263A (en) | 1991-03-15 | 1993-03-30 | The United States Of America As Represented By The United States Department Of Energy | High rate chemical vapor deposition of carbon films using fluorinated gases |
US5199942A (en) | 1991-06-07 | 1993-04-06 | Immunex Corporation | Method for improving autologous transplantation |
US5302168A (en) | 1991-09-05 | 1994-04-12 | Hess Robert L | Method and apparatus for restenosis treatment |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5464450A (en) | 1991-10-04 | 1995-11-07 | Scimed Lifesystems Inc. | Biodegradable drug delivery vascular stent |
GB9203037D0 (en) * | 1992-02-11 | 1992-03-25 | Salutar Inc | Contrast agents |
US5302166A (en) * | 1992-02-21 | 1994-04-12 | Optima Industries, Inc. | Tool changer |
US5310669A (en) | 1992-06-22 | 1994-05-10 | The Trustees Of Dartmouth College | Fullerene coated surfaces and uses thereof |
US6306421B1 (en) * | 1992-09-25 | 2001-10-23 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5292813A (en) | 1992-10-02 | 1994-03-08 | Exxon Research & Engineering Co. | Fullerene-grafted polymers and processes of making |
US5981568A (en) * | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5338571A (en) | 1993-02-10 | 1994-08-16 | Northwestern University | Method of forming self-assembled, mono- and multi-layer fullerene film and coated substrates produced thereby |
US5464650A (en) | 1993-04-26 | 1995-11-07 | Medtronic, Inc. | Intravascular stent and method |
US5641466A (en) | 1993-06-03 | 1997-06-24 | Nec Corporation | Method of purifying carbon nanotubes |
US5558903A (en) | 1993-06-10 | 1996-09-24 | The Ohio State University | Method for coating fullerene materials for tribology |
US6120764A (en) | 1993-06-24 | 2000-09-19 | Advec, Inc. | Adenoviruses for control of gene expression |
US5830760A (en) | 1993-07-28 | 1998-11-03 | Fred Hutchinson Cancer Research Center | Creating novel hematopoietic cell lines by expressing altered retinoic acid receptors |
EP0722331A4 (en) | 1993-08-25 | 1997-10-01 | Systemix Inc | Method for producing a highly enriched population of hematopoietic stem cells |
US6323184B1 (en) * | 1993-10-15 | 2001-11-27 | Thomas Jefferson University | Arteriovenous and venous graft treatments: methods and compositions |
ATE241394T1 (en) | 1994-04-08 | 2003-06-15 | Atrix Lab Inc | ASSOCIATED POLYMER SYSTEM FOR USE WITH A MEDICAL DEVICE |
US5536641A (en) | 1994-05-17 | 1996-07-16 | Memorial Sloane Kittering Cancer Center | Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1 and uses thereof for detection of, and isolation of, vascular endothelial cells |
GB9413029D0 (en) | 1994-06-29 | 1994-08-17 | Common Services Agency | Stem cell immobilisation |
US6249703B1 (en) | 1994-07-08 | 2001-06-19 | Medtronic, Inc. | Handheld patient programmer for implantable human tissue stimulator |
AU700584C (en) | 1994-08-12 | 2002-03-28 | Meadox Medicals, Inc. | Vascular graft impregnated with a heparin-containing collagen sealant |
US6281015B1 (en) | 1994-12-16 | 2001-08-28 | Children's Medical Center Corp. | Localized delivery of factors enhancing survival of transplanted cells |
US6231600B1 (en) | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
CA2216919C (en) | 1995-03-28 | 2007-09-18 | Fidia Advanced Biopolymers Srl | Nanospheres comprising a biocompatible polysaccharide |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120536A (en) * | 1995-04-19 | 2000-09-19 | Schneider (Usa) Inc. | Medical devices with long term non-thrombogenic coatings |
US5807398A (en) * | 1995-04-28 | 1998-09-15 | Shaknovich; Alexander | Shuttle stent delivery catheter |
US5661127A (en) | 1995-05-01 | 1997-08-26 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
US5780436A (en) | 1995-05-01 | 1998-07-14 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
US5603722A (en) | 1995-06-06 | 1997-02-18 | Quanam Medical Corporation | Intravascular stent |
US5824299A (en) * | 1995-06-22 | 1998-10-20 | President & Fellows Of Harvard College | Modulation of endothelial cell proliferation with IP-10 |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6090618A (en) * | 1996-10-07 | 2000-07-18 | Arch Development Corporation | DNA constructs and viral vectors comprising a smooth muscle promoter |
US5669924A (en) * | 1995-10-26 | 1997-09-23 | Shaknovich; Alexander | Y-shuttle stent assembly for bifurcating vessels and method of using the same |
CA2239775C (en) * | 1995-12-18 | 2008-07-15 | Collagen Corporation | Crosslinked polymer compositions and methods for their use |
US5865723A (en) | 1995-12-29 | 1999-02-02 | Ramus Medical Technologies | Method and apparatus for forming vascular prostheses |
US6051017A (en) | 1996-02-20 | 2000-04-18 | Advanced Bionics Corporation | Implantable microstimulator and systems employing the same |
EP0910340A4 (en) * | 1996-03-06 | 2004-11-17 | Hyperion Catalysis Int | Functionalized nanotubes |
US20040072768A1 (en) * | 1996-03-07 | 2004-04-15 | Khachigian Levon Michael | Inhibition of proliferation of cells |
AUPN855496A0 (en) * | 1996-03-07 | 1996-04-04 | Unisearch Limited | Prevention of proliferation of vascular cells |
JPH09249751A (en) * | 1996-03-14 | 1997-09-22 | Collagn Corp | Use of hydrophobic crosslinking agent for preparing crosslinked biological material composition |
US6413735B1 (en) * | 1996-03-15 | 2002-07-02 | Munin Corporation | Method of screening for a modulator of angiogenesis |
GB9606188D0 (en) | 1996-03-23 | 1996-05-29 | Danbiosyst Uk | Pollysaccharide microspheres for the pulmonary delivery of drugs |
GB9606452D0 (en) | 1996-03-27 | 1996-06-05 | Sandoz Ltd | Organic compounds |
US6455678B1 (en) | 1996-04-26 | 2002-09-24 | Amcell Corporation | Human hematopoietic stem and progenitor cell antigen |
US5843633A (en) | 1996-04-26 | 1998-12-01 | Amcell Corporation | Characterization of a human hematopoietic progenitor cell antigen |
US6143037A (en) * | 1996-06-12 | 2000-11-07 | The Regents Of The University Of Michigan | Compositions and methods for coating medical devices |
DE69703121D1 (en) | 1996-10-25 | 2000-10-19 | Us Health | METHODS AND COMPOSITIONS TO PREVENT INFLAMMATION AND ANGIOGENESIS CONTAINING MAMMALIA CD97 ALPHA UNIT |
US6500421B1 (en) | 1996-11-04 | 2002-12-31 | St. Jude Children's Research Hospital | In vivo selection of primitive hematopoietic cells |
US5980887A (en) | 1996-11-08 | 1999-11-09 | St. Elizabeth's Medical Center Of Boston | Methods for enhancing angiogenesis with endothelial progenitor cells |
AU5173598A (en) * | 1996-11-08 | 1998-06-10 | Ikonos Corporation | Method for coating substrates |
US5749890A (en) * | 1996-12-03 | 1998-05-12 | Shaknovich; Alexander | Method and system for stent placement in ostial lesions |
US5753088A (en) | 1997-02-18 | 1998-05-19 | General Motors Corporation | Method for making carbon nanotubes |
US6258939B1 (en) | 1997-03-10 | 2001-07-10 | The Regents Of The University Of California | PSCA antibodies and hybridomas producing them |
US6238872B1 (en) * | 1997-04-01 | 2001-05-29 | S.E.T.-Smart Endolumenal Technologies Ltd. | Targeted therapy to a biomedical device |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6273913B1 (en) | 1997-04-18 | 2001-08-14 | Cordis Corporation | Modified stent useful for delivery of drugs along stent strut |
US6077987A (en) | 1997-09-04 | 2000-06-20 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
US5880090A (en) * | 1997-09-19 | 1999-03-09 | The Hope Heart Institute | Treatment of vascular graft implants with G-CSF |
US6440734B1 (en) | 1998-09-25 | 2002-08-27 | Cytomatrix, Llc | Methods and devices for the long-term culture of hematopoietic progenitor cells |
US8257725B2 (en) * | 1997-09-26 | 2012-09-04 | Abbott Laboratories | Delivery of highly lipophilic agents via medical devices |
US5945457A (en) * | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
US5980565A (en) | 1997-10-20 | 1999-11-09 | Iowa-India Investments Company Limited | Sandwich stent |
US20020056148A1 (en) | 1997-11-14 | 2002-05-09 | Readhead Carol W. | Transfection, storage and transfer of male germ cells for generation of selectable transgenic stem cells |
ATE426036T1 (en) | 1997-11-14 | 2009-04-15 | Cedars Sinai Medical Center | TRANSFECTION AND TRANSFER OF NON-HUMAN MALE GERM CELLS TO GENERATE TRANSGENIC NON-HUMAN MAMMALS |
US6197586B1 (en) | 1997-12-12 | 2001-03-06 | The Regents Of The University Of California | Chondrocyte-like cells useful for tissue engineering and methods |
EP1039944B1 (en) | 1997-12-19 | 2008-02-20 | Cordis Corporation | Catheter system having fullerenes |
US20020051762A1 (en) | 1998-01-23 | 2002-05-02 | Shahin Rafii | Purified populations of endothelial progenitor cells |
US6541116B2 (en) | 1998-01-30 | 2003-04-01 | Advanced Cardiovascular Systems, Inc. | Superoxide dismutase or superoxide dismutase mimic coating for an intracorporeal medical device |
US20030125615A1 (en) | 1998-02-05 | 2003-07-03 | Yitzhack Schwartz | Homing of autologous cells to a target zone in tissue using active therapeutics or substances |
US6140127A (en) | 1998-02-18 | 2000-10-31 | Cordis Corporation | Method of coating an intravascular stent with an endothelial cell adhesive five amino acid peptide |
US6676937B1 (en) | 1998-03-09 | 2004-01-13 | Caritas St. Elizabeth's Medical Center Of Boston Inc. | Compositions and methods for modulating vascularization |
US6482406B1 (en) | 1999-03-26 | 2002-11-19 | Duncan J. Stewart | Cell-based gene therapy for the pulmonary system |
MXPA00010110A (en) | 1998-04-17 | 2002-08-06 | Angiogenix Inc | Therapeutic angiogenic factors and methods for their use. |
US6206914B1 (en) | 1998-04-30 | 2001-03-27 | Medtronic, Inc. | Implantable system with drug-eluting cells for on-demand local drug delivery |
US6153252A (en) | 1998-06-30 | 2000-11-28 | Ethicon, Inc. | Process for coating stents |
CA2279476C (en) | 1998-07-31 | 2011-09-27 | Stemcell Technologies Inc. | Novel antibody composition for isolating human cells from human-murine chimeric hematopoietic cell suspensions |
US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
JP2000086699A (en) | 1998-09-07 | 2000-03-28 | Seikagaku Kogyo Co Ltd | New monoclonal antibody for recognizing cell surface antigen cd14 |
US7122635B2 (en) * | 1999-01-06 | 2006-10-17 | University Of Southern California | Method and composition for angiogenesis inhibition |
DE19903385A1 (en) | 1999-01-29 | 2000-08-03 | Max Delbrueck Centrum | Agent for the prevention of in-stent restenosis and post-operative inflammation |
US6544541B1 (en) * | 1999-06-02 | 2003-04-08 | Cardiovascular Solutions, Inc. | Devices and compounds for treating arterial restenosis |
EP1183358A1 (en) * | 1999-06-07 | 2002-03-06 | Edwards Lifesciences Corporation | Targeted angiogenesis |
US6258121B1 (en) | 1999-07-02 | 2001-07-10 | Scimed Life Systems, Inc. | Stent coating |
US6159531A (en) | 1999-08-30 | 2000-12-12 | Cardiovasc, Inc. | Coating having biological activity and medical implant having surface carrying the same and method |
US6371980B1 (en) | 1999-08-30 | 2002-04-16 | Cardiovasc, Inc. | Composite expandable device with impervious polymeric covering and bioactive coating thereon, delivery apparatus and method |
WO2001065934A2 (en) * | 2000-03-09 | 2001-09-13 | Lee Walters | Applications of immune system tolerance to treatment of various diseases |
US20050271701A1 (en) | 2000-03-15 | 2005-12-08 | Orbus Medical Technologies, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20160287708A9 (en) * | 2000-03-15 | 2016-10-06 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9320829B2 (en) * | 2000-03-15 | 2016-04-26 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US20030229393A1 (en) | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
US20070141107A1 (en) * | 2000-03-15 | 2007-06-21 | Orbusneich Medical, Inc. | Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) * | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US8460367B2 (en) * | 2000-03-15 | 2013-06-11 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
HUP0300810A2 (en) * | 2000-07-20 | 2003-08-28 | M.G.V.S. Ltd. | Artifical vascular grafts, and methods of producing and using same |
US6607720B1 (en) | 2000-09-05 | 2003-08-19 | Yong-Fu Xiao | Genetically altered mammalian embryonic stem cells, their living progeny, and their therapeutic application for improving cardiac function after myocardial infarction |
US6548025B1 (en) | 2000-11-08 | 2003-04-15 | Illinois Institute Of Technology | Apparatus for generating odor upon electronic signal demand |
US6471980B2 (en) | 2000-12-22 | 2002-10-29 | Avantec Vascular Corporation | Intravascular delivery of mycophenolic acid |
WO2002092108A1 (en) | 2001-05-11 | 2002-11-21 | Children's Medical Center Corporation ¨ | Methods for assessing antiangiogenic agents |
WO2002096195A1 (en) | 2001-05-31 | 2002-12-05 | Enteromed, Inc. | Treatment or replacement therapy using transgenic stem cells delivered to the gut |
DE10148828B4 (en) * | 2001-10-04 | 2005-05-19 | Avontec Gmbh | Modulation of the expression of STAT-1-dependent genes |
AU2002359340A1 (en) * | 2001-10-31 | 2003-05-12 | Ventrigraft Inc | Methods and device compositions for the recruitment of cells to blood contacting surfaces in vivo |
AU2003217271A1 (en) * | 2002-01-29 | 2003-09-02 | A. Mark Colb | Endothelialization of vascular surfaces |
AUPS078002A0 (en) * | 2002-02-27 | 2002-03-21 | Unisearch Limited | Dnazyme therapeutics |
US20030181973A1 (en) | 2002-03-20 | 2003-09-25 | Harvinder Sahota | Reduced restenosis drug containing stents |
JP4136434B2 (en) | 2002-04-17 | 2008-08-20 | 進 清野 | Induction of insulin-producing cells |
WO2003099169A1 (en) | 2002-05-20 | 2003-12-04 | Orbus Medical Technologies Inc. | Drug eluting implantable medical device |
EP1410812A1 (en) | 2002-10-14 | 2004-04-21 | EC (European Community) | Functionalisation of stents with lipase |
US7208190B2 (en) * | 2002-11-07 | 2007-04-24 | Abbott Laboratories | Method of loading beneficial agent to a prosthesis by fluid-jet application |
CA2511665A1 (en) * | 2002-12-18 | 2004-07-01 | Novartis Ag | Endothelial cell specifically binding peptides |
US7186882B2 (en) * | 2003-03-18 | 2007-03-06 | Nasrin Mesaeli | Transgenic mouse over-expressing calreticulin (CRT) in vascular smooth muscle cells |
US20050107870A1 (en) * | 2003-04-08 | 2005-05-19 | Xingwu Wang | Medical device with multiple coating layers |
US20050149174A1 (en) | 2003-12-18 | 2005-07-07 | Medtronic Vascular, Inc. | Medical devices to treat or inhibit restenosis |
US20050187607A1 (en) * | 2004-02-20 | 2005-08-25 | Akhtar Adil J. | Drug delivery device |
US8431145B2 (en) * | 2004-03-19 | 2013-04-30 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
AU2005222719B2 (en) * | 2004-03-19 | 2011-03-24 | Abbott Laboratories | Multiple drug delivery from a balloon and a prosthesis |
EP2946666B1 (en) | 2004-04-30 | 2017-11-15 | OrbusNeich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods of using same |
US7959942B2 (en) * | 2006-10-20 | 2011-06-14 | Orbusneich Medical, Inc. | Bioabsorbable medical device with coating |
US8691321B2 (en) * | 2006-10-20 | 2014-04-08 | Orbusneich Medical, Inc. | Bioabsorbable polymeric composition and medical device background |
WO2008144616A1 (en) * | 2007-05-18 | 2008-11-27 | Heidi Kay | Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods |
WO2009130296A2 (en) * | 2008-04-25 | 2009-10-29 | Morphosys Ag | Anti-alk1 antibodies and uses thereof |
US9217042B2 (en) * | 2012-10-23 | 2015-12-22 | Abbott Cardiovascular Systems Inc. | Method of reducing MACE in diabetic patients subsequent to stent placement |
-
2001
- 2001-03-15 ES ES01918685T patent/ES2283398T3/en not_active Expired - Lifetime
- 2001-03-15 AU AU2001245734A patent/AU2001245734A1/en not_active Abandoned
- 2001-03-15 EP EP01918685A patent/EP1263484B1/en not_active Expired - Lifetime
- 2001-03-15 AT AT01918685T patent/ATE362382T1/en not_active IP Right Cessation
- 2001-03-15 CN CNB018066801A patent/CN100506293C/en not_active Expired - Lifetime
- 2001-03-15 KR KR1020027012043A patent/KR100860860B1/en not_active IP Right Cessation
- 2001-03-15 CA CA002400319A patent/CA2400319C/en not_active Expired - Lifetime
- 2001-03-15 JP JP2001566720A patent/JP5859179B2/en not_active Expired - Lifetime
- 2001-03-15 DE DE60128451T patent/DE60128451T2/en not_active Expired - Lifetime
- 2001-03-15 WO PCT/US2001/008244 patent/WO2001068158A1/en active IP Right Grant
- 2001-03-15 US US09/808,867 patent/US7037332B2/en not_active Expired - Lifetime
- 2001-03-15 IL IL15150101A patent/IL151501A0/en not_active IP Right Cessation
-
2004
- 2004-04-26 US US10/832,106 patent/US7803183B2/en not_active Expired - Fee Related
-
2006
- 2006-11-22 US US11/562,931 patent/US20070156232A1/en not_active Abandoned
-
2012
- 2012-08-20 US US13/589,907 patent/US9072723B2/en not_active Expired - Fee Related
- 2012-10-05 JP JP2012222595A patent/JP5675744B2/en not_active Expired - Lifetime
-
2015
- 2015-01-29 JP JP2015016115A patent/JP2015128598A/en active Pending
- 2015-06-05 US US14/732,489 patent/US9555166B2/en not_active Expired - Lifetime
- 2015-08-21 US US14/831,956 patent/US20150352263A1/en not_active Abandoned
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5543328A (en) * | 1993-08-13 | 1996-08-06 | Genetic Therapy, Inc. | Adenoviruses having modified fiber proteins |
US6342390B1 (en) * | 1994-11-23 | 2002-01-29 | The United States Of America As Represented By The Secretary Of Health And Human Services | Lipid vesicles containing adeno-associated virus rep protein for transgene integration and gene therapy |
US6171609B1 (en) * | 1995-02-15 | 2001-01-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US6464889B1 (en) * | 1996-01-22 | 2002-10-15 | Etex Corporation | Surface modification of medical implants |
US6790606B1 (en) * | 1996-03-15 | 2004-09-14 | Munin Corporation | Extracellular matrix signaling molecules |
US6583276B1 (en) * | 1996-09-06 | 2003-06-24 | Technion Research And Development Co., Ltd. | Angiogenic factors and use thereof in treating cardiovascular disease |
US6673341B2 (en) * | 1998-07-06 | 2004-01-06 | Beth Israel Deaconness Medical Center | Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis |
US6607724B2 (en) * | 1998-10-08 | 2003-08-19 | Children's Hospital | Compositions and methods for inhibiting angiogenesis |
US6375680B1 (en) * | 1998-12-01 | 2002-04-23 | St. Jude Medical, Inc. | Substrates for forming synthetic tissues |
US6503273B1 (en) * | 1999-11-22 | 2003-01-07 | Cyograft Tissue Engineering, Inc. | Tissue engineered blood vessels and methods and apparatus for their manufacture |
US7037332B2 (en) * | 2000-03-15 | 2006-05-02 | Orbus Medical Technologies, Inc. | Medical device with coating that promotes endothelial cell adherence |
US6613083B2 (en) * | 2001-05-02 | 2003-09-02 | Eckhard Alt | Stent device and method |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9517203B2 (en) | 2000-08-30 | 2016-12-13 | Mediv As, Llc | Polymer particle delivery compositions and methods of use |
US20030229393A1 (en) * | 2001-03-15 | 2003-12-11 | Kutryk Michael J. B. | Medical device with coating that promotes cell adherence and differentiation |
US20050238689A1 (en) * | 2004-04-05 | 2005-10-27 | Medivas, Llc | Bioactive stents for type II diabetics and methods for use thereof |
US20110137406A1 (en) * | 2004-04-05 | 2011-06-09 | Medivas, Llc | Bioactive stents for type ii diabetics and methods for use thereof |
US8163269B2 (en) | 2004-04-05 | 2012-04-24 | Carpenter Kenneth W | Bioactive stents for type II diabetics and methods for use thereof |
US8652504B2 (en) | 2005-09-22 | 2014-02-18 | Medivas, Llc | Solid polymer delivery compositions and methods for use thereof |
US9102830B2 (en) | 2005-09-22 | 2015-08-11 | Medivas, Llc | Bis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use |
US20100040664A1 (en) * | 2008-08-13 | 2010-02-18 | Medivas, Llc | Aabb-poly(depsipeptide) biodegradable polymers and methods of use |
US9205177B2 (en) | 2009-03-04 | 2015-12-08 | Peytant Solutions, Inc. | Stents modified with material comprising amnion tissue and corresponding processes |
US20100228335A1 (en) * | 2009-03-04 | 2010-09-09 | John Schorgl | Stents modified with material comprising amnion tissue and corresponding processes |
US20110125251A1 (en) * | 2009-05-14 | 2011-05-26 | Orbusneich Medical, Inc. | Self-Expanding Stent with Polygon Transition Zone |
US9572693B2 (en) | 2009-05-14 | 2017-02-21 | Orbusneich Medical, Inc. | Self-expanding stent with polygon transition zone |
WO2012121507A3 (en) * | 2011-03-10 | 2012-12-20 | 서울대학교 산학협력단 | Stent able to selectively capture vascular endothelial progenitor cells and a production method therefor |
WO2012121507A2 (en) * | 2011-03-10 | 2012-09-13 | 서울대학교 산학협력단 | Stent able to selectively capture vascular endothelial progenitor cells and a production method therefor |
KR101770827B1 (en) * | 2011-03-10 | 2017-08-23 | 서울대학교산학협력단 | Stent for selectively capturing epc and process for producing the same |
US9896544B2 (en) | 2011-06-23 | 2018-02-20 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
US9873764B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Particles comprising polyesteramide copolymers for drug delivery |
US9873765B2 (en) | 2011-06-23 | 2018-01-23 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
US9963549B2 (en) | 2011-06-23 | 2018-05-08 | Dsm Ip Assets, B.V. | Biodegradable polyesteramide copolymers for drug delivery |
US20170340463A1 (en) * | 2014-11-11 | 2017-11-30 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Super elastic, bioabsorbable endovascular devices |
US10888442B2 (en) * | 2014-11-11 | 2021-01-12 | University of Pittsburgh—of the Commonwealth System of Higher Education | Super elastic, bioabsorbable endovascular devices |
US10434071B2 (en) | 2014-12-18 | 2019-10-08 | Dsm Ip Assets, B.V. | Drug delivery system for delivery of acid sensitivity drugs |
US10888531B2 (en) | 2014-12-18 | 2021-01-12 | Dsm Ip Assets B.V. | Drug delivery system for delivery of acid sensitivity drugs |
US11202762B2 (en) | 2014-12-18 | 2021-12-21 | Dsm Ip Assets B.V. | Drug delivery system for delivery of acid sensitivity drugs |
Also Published As
Publication number | Publication date |
---|---|
CA2400319C (en) | 2008-09-16 |
CA2400319A1 (en) | 2001-09-20 |
EP1263484A1 (en) | 2002-12-11 |
DE60128451T2 (en) | 2007-08-30 |
US20130035755A1 (en) | 2013-02-07 |
US20050043787A1 (en) | 2005-02-24 |
JP5675744B2 (en) | 2015-02-25 |
IL151501A0 (en) | 2003-04-10 |
US9072723B2 (en) | 2015-07-07 |
DE60128451D1 (en) | 2007-06-28 |
JP2003526477A (en) | 2003-09-09 |
AU2001245734A1 (en) | 2001-09-24 |
US20150352261A1 (en) | 2015-12-10 |
CN100506293C (en) | 2009-07-01 |
JP2013046771A (en) | 2013-03-07 |
US20020049495A1 (en) | 2002-04-25 |
US7803183B2 (en) | 2010-09-28 |
ATE362382T1 (en) | 2007-06-15 |
JP2015128598A (en) | 2015-07-16 |
KR100860860B1 (en) | 2008-09-29 |
US20150352263A1 (en) | 2015-12-10 |
KR20030001378A (en) | 2003-01-06 |
US7037332B2 (en) | 2006-05-02 |
ES2283398T3 (en) | 2007-11-01 |
EP1263484B1 (en) | 2007-05-16 |
WO2001068158A1 (en) | 2001-09-20 |
CN1418115A (en) | 2003-05-14 |
US9555166B2 (en) | 2017-01-31 |
JP5859179B2 (en) | 2016-02-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9555166B2 (en) | Medical device with coating that promotes endothelial cell adherence | |
CA2472031C (en) | Medical device with coating that promotes endothelial cell adherence and differentiation | |
EP2946666B1 (en) | Medical device with coating for capturing genetically-altered cells and methods of using same | |
US9522217B2 (en) | Medical device with coating for capturing genetically-altered cells and methods for using same | |
US20130172988A1 (en) | Medical device with coating that promotes endothelial cell adherence and differentiation | |
US20060135476A1 (en) | Medical device with coating that promotes endothelial cell adherence and differentiation | |
US20070191932A1 (en) | Medical device with coating for capturing genetically-altered cells and methods for using same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ORBUSNEICH MEDICAL PTE. LTD., SINGAPORE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ORBUSNEICH MEDICAL, INC.;REEL/FRAME:048043/0879 Effective date: 20181101 |